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1 INTRODUCTION 
1.1 Chemotherapy of solid cancers 
Since the first successful application of nitrogen mustard chemotherapy to control 
non-Hodgkin lymphoma in the 1940s, researchers around the world are on a hunt for 
new, improved treatment options to cure cancer patients. In the following years 
several fruitful discoveries of effective treatments were made [1]. In 1951, 
methotrexate was introduced as the first solid cancer chemotherapy for the treatment 
of breast carcinoma. Seven years later the first cure of a solid tumor by drug therapy 
was achieved by a methotrexate treatment of choriocarcinoma. After the discovery of 
the antitumor effect of vinca alkaloids (1950s) such as vincristine (FDA market 
approval in 1963), researchers screened other natural compounds for cytotoxic 
potential. This resulted in the discovery of taxanes (1964) and camptothecins (1966) 
[2]. Another important class of chemotherapeutics was serendipitously discovered by 
Barnett Rosenberg in the 1970s. During experiments that involved electric field 
generation using platinum electrodes he discovered, that the division of bacteria cells 
was ceased. His investigations of the phenomenon revealed, that cis-[Pt(NH3)2Cl2] 
(cisplatin, Figure 1) was the effective component inhibiting the cell division [3]. During 
the following clinical investigations in cancer patients it was found that cisplatin was 
highly effective against testicular cancer. The FDA approved cisplatin in 1978 for the 
treatment of patients suffering from testicular and ovarian cancer [4]. In 1989 the 
research on new platinum drugs with an improved side effect profile led to the 
approval of the second generation platinum drug carboplatin (Figure 1) for the 
treatment of ovarian cancer. In 2002, the third generation platinum drug oxaliplatin 
2 INTRODUCTION 
 
(Figure 1) gained FDA approval for colorectal cancer [5]. Today, these 
chemotherapeutics are used as monotherapy or in combination chemotherapy 
regimens with various other treatment options such as surgery or radiotherapy. This 
way some cancer entities can be cured effectively by platinum-based chemotherapy, 
such as testicular cancer. Other entities, like lung cancer, can be effectively 
controlled. 
 
Figure 1 Platinum complexes approved for clinical use: cisplatin, carboplatin and 
oxaliplatin (left to right). 
Over the past twenty years, the introduction of targeted therapies to the treatment 
arsenal led to the next developmental stage in cancer treatment [6]. The first targeted 
therapy that achieved FDA market authorization was imatinib in 2001 [7]. Identified 
drug targets include growth factors, signaling molecules and cell-cycle proteins which 
may be inhibited or otherwise hindered [8]. Results for the combination of targeted 
therapies with traditional chemotherapeutics are contradictory depending on cancer 
entity and therapy, showing either no benefit for the patients or promising 
improvements of survival [9–11]. A concept followed by some researchers involved 
the activation of the human immune system to treat cancer [12]. After decades of 
research, cancer immunotherapy proved its efficacy in the treatment of a variety of 
tumors and was entitled as ‘Breakthrough of the year 2013’ by Science [13,14]. More 
research is needed, as its use is currently limited by the fact that only a minority of 
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cancer patients benefits from immunotherapy so far [15]. Many scientists believe that 
the future of chemotherapy lies in personalized medicine. Treating only those 
patients who will benefit from a drug may stall the financially, scientifically and 
ethically unacceptable tradition of treating many patients although it is effective only 
in a few [1,16]. 
Overall the use of chemotherapy to treat cancer is a success story. From 1990 to 
2013, a decrease by around 15% in the age-standardized death rate per 100000 
persons for all cancer entities was registered [17]. However, this decline can be 
attributed not only to the use of improved chemotherapies but also to an increased 
success of prevention and early diagnosis [18]. Still, cancer is in many cases a life-
threatening disease, which needs further research efforts to be better controlled and 
treated. 
1.2 Cisplatin 
1.2.1 Mechanism of action 
Over the past four decades researchers elucidated the mechanism of action of 
cisplatin. The most widely accepted hypothesis states that the cytotoxic effect of 
cisplatin is due to its ability to bind nuclear DNA thus initiating the programmed cell 
death (apoptosis) [19]. Cisplatin enters a cell by passive diffusion, uptake through 
gated channels [20], or via active transporters [21]. These mechanisms most 
probably act simultaneously during cellular uptake [22]. The role of active transport 
has been elucidated in recent years and differences between the various transporters 
have been discovered. Evidence suggests, for example, that the active transport of 
cisplatin over copper transporters (CTR) contributes to the cytotoxic effect [21,23]. 
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As a result of a significantly decreased chloride ion concentration inside the cell (3-
20 mM) compared to the extracellular space (100 mM), cisplatin is activated by 
hydrolysis (Figure 2) [24]. The resulting mono- or diaqua species are highly reactive. 
 
Figure 2 Schematic representation of the stepwise bioactivation of cisplatin in the 
cytoplasm, modified according to [25].  
On its way from the cell membrane to the nucleus, several adduct formation 
reactions of reactive cisplatin species with small nucleophilic ligands and proteins 
may potentially occur. A small proportion (around 1%) of the intracellular cisplatin 
reaches the nucleus where the pharmacologically relevant binding to nuclear DNA 
takes place. This subsequently activates several cellular processes, which ultimately 
lead to cell death [26,27]. Early research elucidated that reactive cisplatin species 
form covalent bonds preferably at the N-7 position of the DNA bases adenine and 
guanine [28,29]. The resulting bifunctional adducts mainly lead to intrastrand 
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crosslinks (80 to 90% of all DNA bound platinum). Interstrand crosslinks and 
monofunctional adducts only account for less than 5% of all adducts (Figure 3) [5]. 
The cytotoxic effect of cisplatin is mainly attributed to the 1,2-intrastrand crosslinks 
due to the following: (a) these are the major adducts formed in vitro and in vivo and 
(b) the clinically inactive transplatin is unable to form such links [30]. 
 
Figure 3 Cisplatin DNA adducts and their respective prevalence (modified after [31]). 
A = adenine, G = guanine, N = nucleoside 
1.2.2 Clinical relevance 
Today cisplatin is among the most widely used chemotherapeutic drugs for various 
cancer entities [24]. It plays a central role in the treatment of testicular cancer and 
germ cell tumors [32]. More than 90% of testicular cancer patients with ‘good risk’ 
disease according to the MSKCC criteria can be cured using chemotherapy 
regimens, which often include cisplatin [33]. Most patients are treated with the BEP 
regimen, which consists of a combination of bleomycin, etoposide and cisplatin.  
Furthermore, cisplatin is used in the treatment of gastric and esophageal cancer in 
combination with surgery and radiotherapy [34,35]. For these cancer entities, the 
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outcome is not as encouraging as for testicular cancer. Single agent chemotherapy 
with cisplatin showed a response rate of only 10% to 20% for esophageal cancer 
patients. By addition of fluorouracil and paclitaxel to cisplatin therapy the response 
rates are improved to around 50% [36]. 
Small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are the most 
frequent cause of cancer death worldwide. Besides tumor resection, cisplatin 
remains a cornerstone of therapy for these tumor entities [37,38]. Treatment 
guidelines for SCLC recommend a platinum-based chemotherapy in combination 
with etoposide for patients with extensive disease, reaching response rates ranging 
from 50 to 90% [39]. In a recent review no benefit of newer cytotoxic agents 
compared to standard platinum-based therapy for SCLC was reported, emphasizing 
the importance of the platinum drug in the management of SCLC [40]. In advanced 
NSCLC, platinum-based therapies were more effective than third-generation 
regimens including gemcitabine or paclitaxel [41]. Adjuvant chemotherapy with a two-
drug, cisplatin-based regimen has been shown to increase the 5-year survival only by 
4 to 5% in resected NSCLC patients [42]. 
Only 20% of all ovarian cancer patients are diagnosed early at stage 1 where the 
disease is limited to the ovaries. In most cases the disease has metastasized to the 
pelvic organs (stage 2), the abdomen (stage 3) or beyond the peritoneal cavity (stage 
4) [43]. In ovarian cancer patients bearing stage 2-4 tumors, cisplatin is mostly used 
in therapy regimens in combination with paclitaxel, whereas stage 1 tumors are 
treated with a combination of carboplatin and paclitaxel [44]. First-line therapy is 
successful in a majority of patients, but clinical studies showed that more than 70% of 
patients develop a recurrent disease after a period of time. These patients often 
obtain some degree of acquired cisplatin resistance [45]. The median survival of 
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patients with recurrent disease depends on the tumor’s platinum sensitivity. Patients 
with platinum-sensitive disease have a median overall survival of 2 years, whereas 
patients with platinum-resistant disease have a median overall survival of below one 
year (9 to 12 months) [46]. In a recent phase I clinical trial, an alternative to the 
standard intravenous therapy to treat patients with platinum-sensitive, recurrent 
epithelial ovarian cancer has been evaluated. Cisplatin was administered 
intraperitoneally after a cytoreductive surgery in an attempt to kill residual cancer 
cells by an elevated local cisplatin exposition [47]. The procedure is currently under 
investigation in further clinical trials, hopefully adding another option to the treatment 
arsenal for ovarian cancer [48,49]. Clinical studies revealed that carboplatin shows 
an improved side effect profile while exhibiting equal efficacy in some stages of 
ovarian cancer [50]. Therefore, cisplatin is sometimes replaced by carboplatin in 
therapy regimens for ovarian cancer [4]. 
1.2.3 Toxicity 
The toxic side effects of cisplatin treatment include but are not limited to emesis and 
oto-, neuro- and nephrotoxicity. Emesis is probably the most disturbing side effect for 
patients undergoing cisplatin treatment. More than 90% of patients without an 
effective antiemetic therapy will suffer from nausea and vomiting, which classifies 
cisplatin as a highly emetogenic drug [51]. Today anti-emetic therapies including 5-
HT3 antagonists (e.g. ondansetron) in combination with glucocorticoids 
(dexamethasone) and/or NK1 receptor antagonists (aprepitant) are available limiting 
this side effect effectively [52]. 
Pediatric patients are at high risk for cisplatin-associated ototoxicity, which affects at 
least 60% of them [53]. Ototoxicity appears to be mainly caused by damage of the 
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cochlear hair cells by cisplatin in a dose-dependent manner [54]. Options to prevent 
the ototoxic effect of cisplatin are currently investigated in preclinical and clinical 
studies. However, a recently published Cochrane review found no evidence for any 
effective otoprotective treatment [55]. Therefore, new approaches to manage 
ototoxicity are evaluated. For example, in an animal model in guinea pigs ototoxicity 
was reduced by intracochlear administration of caspase inhibitors during cisplatin 
therapy in an attempt to limit the apoptosis-inducing effect of cisplatin [56]. 
If cisplatin is combined with other potentially neurotoxic agents, such as paclitaxel, 
development of sensory peripheral neuropathy is a major toxicity [57,58]. As 
previously described, cisplatin unfolds its activity through DNA platination. This 
seems to be the cause for the neurotoxic effect as well, as it harms peripheral nerves 
and dorsal root ganglia neurons, leading to acute and chronic platinum-induced 
neurotoxicity [59]. Despite the evaluation of many promising approaches, no effective 
treatment to control the therapy-induced neuropathy has been found yet [60].  
For the management of the similarly severe nephrotoxicity some therapeutic 
approaches are available, such as volume expansion with sodium chloride or the 
prolongation of infusion time [51]. Importantly, chemotherapeutic efficacy of cisplatin 
must not be undermined by the measures taken [61]. Involved in the nephrotoxicity of 
cisplatin are organic cation transporters (OCT), facilitating the uptake of cisplatin into 
renal tubular cells [62,63]. A high OCT2 expression has been shown at the 
basolateral side of all three segments of the proximal tubule, giving a possible 
explanation for this phenomenon [64]. Recently, Sprowl et al. reported that the OCT2 
inhibitor cimetidine limits cisplatin-induced nephrotoxicity in an animal model without 
altering the antitumor efficacy [65]. 
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1.2.4 Mechanisms of acquired resistance 
Acquired drug resistance is a major setback to successful therapy especially of 
ovarian cancer and compromises the effective outcome of chemotherapy. Several 
mechanisms underlying chemoresistance have been postulated and experimental 
evidence points to a multifactorial nature (Figure 4). Many of the mechanisms 
prevent cisplatin from reaching its therapeutic target, the nuclear DNA, in adequate 
levels to trigger cellular mechanisms leading to cell death (reviewed in [67]). These 
‘pre-target effects’ include but are not limited to a reduced cellular uptake and an 
increased efflux of cisplatin. Furthermore, an increased inactivation of cisplatin by 
nucleophilic scavengers prior to DNA binding has been postulated as a mechanism 
of resistance, which is portrayed in more detail in chapter 1.2.5. 
 
Figure 4 Proposed mechanisms of acquired cisplatin resistance (modified after [66]). 
Intracellular accumulation of cisplatin ultimately results from the interplay between 
drug influx and drug efflux [24]. As already mentioned the uptake/influx of cisplatin is 
mediated simultaneously by passive diffusion, gated channels, and active transport. 
The important contribution of the copper transporter 1 (CTR1) to the regulation of 
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cisplatin uptake in cancer cells sensitive and, even more crucially, resistant to 
cisplatin has been shown by several lines of evidence [68]. Cells resistant to cisplatin 
exhibited cross-resistance to copper, and influx rates for both cisplatin and copper 
were simultaneously reduced [69]. CTR1-deficient fibroblasts showed a significantly 
decreased cisplatin uptake compared to wild-type fibroblasts [70]. Cellular 
accumulation is furthermore influenced by an increased cisplatin efflux, associated 
with an upregulation of the copper-transporting ATPase 1 and 2 (ATP7A and ATP7B) 
in resistant cancer cells [69,71]. Other efflux transporters likely to be involved in 
cisplatin resistance are multidrug resistance-associated proteins (MRP) [72]. MRP2 
appears to play a dominant role in cisplatin resistance compared to other members of 
the family [73]. This manifests for example in the potential of a MRP2 knockdown to 
increase sensitivity to cisplatin in human ovarian cancer cells [74]. Moreover, in the 
clinical setting an increased MRP2 expression conferred cisplatin resistance in 
ovarian cancer [75]. 
As mentioned, nuclear DNA appears to be the main target for cisplatin’s cytotoxic 
action. On-target mechanisms such as the nucleotide excision repair (NER) and the 
replicative bypass also contribute to the multifactorial resistance. The NER system 
enables a cell to remove a majority of platinum adducts from DNA [76]. After the 
recognition of DNA lesions, they are excised by e.g. DNA excision repair protein 
(ERCC1). To maintain the genetic integrity, the DNA synthesis is accomplished by 
the same proteins involved in DNA replication such as replication protein A (RPA), 
polymerase delta and epsilon (Pol δ and Pol ε), and others [77]. The replicative 
bypass, also known as translesion synthesis, enables the cell to synthesize DNA 
past the site of DNA damage [78]. This function is mediated by different DNA 
polymerases such as POLH, POLI or POLK [79]. The mismatch repair system (MMR) 
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is a further cellular mechanism to detect erroneous insertions or deletions of bases 
during DNA replication [80]. This system is also able to recognize DNA lesions 
induced by cisplatin. Mainly the DNA mismatch repair proteins Msh2 (MSH2) and 
Mlh1 (MLH1) are attributed to the transmission of proapoptotic signals after the 
detection of cisplatin-DNA adducts [81] and mutation or loss of expression of MSH2 
and MLH1 protein in acquired cisplatin resistance has been reported [82–84]. 
The DNA damage induced by cisplatin leads to activation of proapoptotic cellular 
signaling. Several genetic and epigenetic alterations of the cell death machinery, 
which contribute to cellular survival can be classified as ‘post-target resistance’ 
(reviewed in [66]). Loss of proapoptotic signaling by inactivation of tumor suppressor 
53 (TP53) confers cisplatin resistance to cancer cells [85,86]. This alteration can be 
found in almost 50% of all human carcinomas that have been investigated [87]. Other 
genetic alterations, e.g. in proapoptotic mitogen-activated protein kinases (MAPK), 
are discussed for their possible contribution to acquired cisplatin resistance [88]. 
Mechanisms of resistance that are independent of DNA platination are termed ‘off-
target’. This description includes, for example, autophagy as a response to 
chemotherapy-induced stress. By lysosomal sequestration and degradation of 
organelles cellular survival is promoted [89]. Other off-target mechanisms 
contributing to cisplatin resistance need to be further investigated. The discussed 
mechanisms include induced expression of heat shock proteins (HSP) and induction 
of other intracellular signaling pathways [66]. 
In order to identify cellular adaptations on the protein level in resistant cell lines, 
researchers evaluated the differences in protein expression in sensitive and resistant 
cancer cells by 2D gel electrophoresis [90–93]. This proteomic approach revealed 
several differentially expressed proteins, among others stress response proteins, 
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such as 78 kDa glucose-regulated protein (GRP78) and cell cycle proteins (Annexin, 
14-3-3 epsilon). The identified proteins do not necessarily bind cisplatin, but may be 
involved in cellular mechanisms promoting resistance. 
At the moment, the evidence for a multifactorial nature of cisplatin resistance is 
solidified. Most recent hypotheses proposed, that several of the above described 
non-overlapping mechanisms occur simultaneously limiting the cytotoxic effect of 
cisplatin (Figure 4). This partly explains why, despite intensive research, there is still 
a lack of efficient strategies to overcome or at least manage acquired cisplatin 
resistance [94]. 
1.2.5 Intracellular binding as a mechanism of resistance 
Inside a tumor cell a plethora of potential binding partners for cisplatin exist. Among 
the early discovered low molecular weight binding partners of cisplatin was 
glutathione (GSH) and small, cytoplasmic proteins of the metallothionein family (MT) 
[95–98]. GSH consists of the three amino acids glutamic acid, cysteine and glycine. 
MT proteins are rich in the sulfur-containing amino acids cysteine and methionine 
[99]. Cysteine and methionine are known to avidly bind cisplatin [100]. In 1995 Goto 
et al. showed that an acquired resistance phenotype of cancer cells may be 
attributed to increased detoxification of cisplatin by GSH [101]. However, in 2009 
Kasherman et al. found that two-thirds of platinum-adducts in whole cell extracts of 
ovarian cancer cells treated with cisplatin had a molecular mass greater than 3 kDa. 
This result suggested that GSH plays only a minor role in cisplatin detoxification, 
whereas other binding partners are of greater importance [102]. More recently, 
proteins were moved into the focus of research on intracellular binding of cisplatin 
[103]. The interaction of cisplatin with proteins appears to be an important factor 
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altering its intracellular distribution, elimination, and ultimately cytotoxicity. Various 
proteomic approaches identified intracellular cisplatin-interaction partners. Using an 
agarose pull-down assay several proteins binding to two different platinum-agarose 
conjugates, among them GRP78 and others were found [104]. The authors 
suggested that these proteins may play a role in platinum-associated nephro- and 
ototoxicity. Interesting results were obtained by in-cell NMR spectroscopy, where an 
intracellular interaction of cisplatin with antioxidant protein 1 (Atox1) was 
investigated. It was shown, that cisplatin forms an adduct with Atox1, and that the 
overexpression of Atox1 reduced DNA platination in E. Coli [105]. Taken together the 
knowledge on the contribution of the identified proteins to acquired cisplatin 
resistance remains limited. Most studies present only a snapshot view of the complex 
cellular interplay of mechanisms [106]. 
It has to be noted that all cisplatin interactions with non-DNA targets may contribute 
to the acquired cisplatin resistance but at the same time may serve as a drug 
reservoir for cisplatin as postulated by Reedijk. Platinum could be released from its 
interaction partners after some time and subsequently react with DNA [107]. This 
would lead to an increase in cytotoxicity of cisplatin and may explain a delayed effect 
of cisplatin. 
1.3 CFDA-cisplatin as model complex for intracellular cisplatin 
analysis 
Due to the currently limited analytical procedures regarding the non-invasive 
speciation of platinum complexes inside a cell, researchers need to employ model 
complexes in order to study the intracellular interactions of cisplatin [108]. In 2000 
Molenaar et al. introduced a fluorescent cisplatin analogue (CFDA-cisplatin or CFDA-
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Pt) by covalently linking a carboxyfluorescein diacetate moiety to cisplatin (Figure 5) 
as a model substance for research [109]. After cellular uptake, the two acetate 
groups of the non-fluorescent CFDA moiety are hydrolyzed by cellular esterases, 
resulting in a fluorescent molecule.  
 
Figure 5 Chemical structure of CFDA-cisplatin. 
With the aid of this model complex, the cellular distribution of cisplatin in cancer cells 
was investigated [109]. Furthermore, it has been shown, that CFDA-cisplatin 
possesses cytotoxic activity in ovarian cancer cells. Interestingly, the same authors 
observed that cisplatin-resistant A2780cis cells were cross-resistant to CFDA-
cisplatin [110]. Further experiments using CFDA-cisplatin revealed that alterations in 
the sub-cellular localization of the transporters ATP7A and ATP7B may contribute to 
the resistant phenotype of A2780cis cells [110]. Intracellular interaction partners of 
CFDA-cisplatin in A2780 and A2780cis cells have recently been identified after 2D 
gel electrophoresis and ESI-MS analysis, among them GRP78 and two protein 
disulfide isomerases (PDIA1, PDIA3) [111].  
It has to be noted, that the addition of a large fluorophore to the small molecule 
cisplatin changes its molecular properties considerably. This limitation needs to be 
recognized and results have to be interpreted accordingly [108]. 
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1.4 Intracellular interaction partners of cisplatin 
1.4.1 78 kDa glucose-regulated protein (GRP78) 
GRP78 belongs to the heat shock proteins (HSP70 family) and acts as a chaperone 
mainly located at the endoplasmic reticulum (ER) [112]. Additionally, expression of 
GRP78 on the cell surface was described in several malignant cell lines [113].  
After ribosomal protein biosynthesis the nascent polypeptides are folded into their 
native state mostly in the ER [114]. If a cell undergoes stress, such as glucose 
deprivation or contact with toxic agents, proteins are potentially folded improperly. 
These ‘misfolded’ proteins aggregate in the cytoplasm and need to be refolded by 
chaperones for correct function [115]. Prolonged ER stress, possibly triggered by 
cisplatin, activates proapoptotic signaling pathways and ultimately leads the cell into 
apoptotic cell death [116]. 
GRP78 acts as a master regulator of the unfolded protein response (UPR) either 
promoting cell survival or cell death depending on the level of ER stress (Figure 6). 
Under normal conditions, GRP78 is bound by three trans-membrane proteins (PKR-
like ER Kinase (PERK), inositol-requiring enzyme 1 (IRE1) and activating 
transcription factor 6 (ATF6)) [117]. If misfolded proteins cumulate in the cytoplasm, 
PERK, IRE1 and ATF6 are released from GRP78 and can exert their functions. 
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Figure 6 Potential signaling pathways after GRP78-mediated activation of ATF6, IRE1 
and PERK depending on time of exposure and intensity of stress (modified after 
[121]). 
The function of PERK is well documented [118]. After release from GRP78, activated 
PERK triggers a signal cascade over ‘E74-like factor 2’ (eIF2) and activating 
transcription factor 4 (ATF4), which leads to a decrease of protein influx into the ER 
promoting cell survival [119]. If the ER stress intensity further increases PERK leads 
to ‘DNA damage-inducible transcript 3 protein’ (CHOP)-mediated activation of the 
proapoptotic proteins ‘Bcl-2-like protein 11’ (Bim), ‘apoptosis regulator BAX’ (Bax), 
and to suppression of the pro-survival protein ‘apoptosis regulator Bcl-2’ (Bcl-2) 
[116,120]. This shifts the balance towards the proapoptotic way, leading the cell into 
apoptosis.  
IRE1 can either activate apoptosis or promote survival and again this depends on the 
extent of ER stress. Following severe, prolonged ER stress IRE1 activates tumor 
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necrosis factor receptor (TNFR)-associated factor-2 (TRAF2), which leads to JNK 
phosphorylation and induction of apoptosis. Another mechanism of IRE1 relies on the 
activation of regulated IRE1-dependent decay (RIDD) protein, which on the one hand 
blocks pro-survival protein X-box binding protein 1 (XBP1), and on the other 
degrades ER-associated mRNA, limiting new protein translation [116]. The inhibition 
of apoptosis by IRE1, on the other hand, is mediated by splicing of XBP1 to XBP1s, 
which leads to an induction of chaperone expression. This increase promotes protein 
folding in the ER, leading to cellular survival [118]. The protease-mediated activation 
of ATF6 in the Golgi apparatus leads to an induction of the expression of 
chaperones, which facilitate the refolding of proteins [122]. There is also evidence, 
that ATF6 is capable of activating CHOP, presenting a possible link between PERK 
and ATF6 in the induction of apoptosis [116]. 
GRP78 localized at the cell surface seems to promote cellular survival. In lung 
carcinoma cells, GRP78 acts as a receptor for the phosphorylation of RAC-alpha 
serine/threonine-protein kinase (Akt) [123]. Induction of Akt/PI3K (phosphoinositide 
3-kinase)-signaling promotes cell proliferation and inhibits apoptosis [124,125]. 
1.4.2 Protein disulfide isomerases 
Protein disulfide isomerases (PDI) are compartmentalized mainly at the endoplasmic 
reticulum (ER) where they exert an oxidoreductase activity catalyzing the formation, 
isomerization and reduction of disulfides [126]. Most PDI isoforms contain an amino 
acid sequence for ER retention, but are also localized in other cellular compartments, 
e.g. the cytosol [127]. PDIA1 (or PDI, P4HB, p55) and PDIA3 (or GRP58, ERp57, 
ERp60) are highly homologous sharing similar amino acid sequences (CGHC: 
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cysteine, glycine, histidine, cysteine) at their active sites [128,129]. Both proteins 
consist of four domains (a, a’, b and b’) (Figure 7).  
 
Figure 7 Domain organization of PDIA1 and PDIA3. Active sites are located in the a and 
a’ domain (modified after [127]). 
The active sites are located in the a and a’ domains, whereas the b and b’ domains 
show some variability between PDIA1 and PDIA3 [127]. The KDEL (lysine, aspartic 
acid, glutamic acid, leucine) ER retention sequence can be found in PDIA1. In PDIA3 
the ER retention is achieved by a QEDL (glutamine, glutamic acid, aspartic acid, 
leucine) sequence [130]. Both PDIA1 and PDIA3 carry seven cysteines, thus 
presenting a possible target for irreversible coordination of platinum complexes, as 
cisplatin binds preferably to cysteine residues [131].  
PDIA1 exerts its chaperone activity mainly depending on its redox status. In order to 
oxidize a substrate dithiol to a disulfide, oxidized PDIA1 is reduced [132]. 
Subsequently, the native state of PDIA1 is reestablished by oxidation of PDIA1 by an 
intracellular oxidant such as glutathione disulfide (GSSG) (Figure 8) [129]. In 
contrast, to perform a reduction reaction PDIA1 is oxidized. The catalytic cycle is 
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finished by reduction of PDIA1 by reductants, such as glutathione (GSH), to the 
native state [133]. 
 
 
Figure 8 Redox reactions of PDI. (A) Oxidation and reduction. (B) Isomerization [132]. 
PDIA1 appears to be a promising target for cancer treatment. Diverse tumor entities, 
such as brain, prostate and ovarian cancer, show a significant upregulation of PDIA1 
[134–137]. Also, in female and male breast cancer cells PDIA1 is overexpressed 
compared to normal tissue [138,139]. Based on these findings the irreversible and 
selective PDIA1 inhibitor PACMA31 was developed and introduced in 2012 by 
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Xu et al. (Figure 9). It has been shown to effectively inhibit the growth of ovarian 
cancer cell lines [140]. 
 
Figure 9 Chemical structure of the irreversible PDIA1 inhibitor PACMA31. 
As PDIA1 and PDIA3 are the most homologous of all known protein disulfide 
isomerases, PDIA3 exerts comparable functions to PDIA1 such as oxidation, 
reduction and isomerization of disulfide bonds [141]. It also mainly localizes at the ER 
[130]. The main difference between PDIA3 and PDIA1 lies in PDIA3’s ability to bind 
calnexin or calreticulin with high affinity, which is needed for the folding of 
glycoproteins [142]. The binding of calnexin and calreticulin occurs at the b and b’ 
domain, which have been shown to be structurally different in PDIA3 compared to 
PDIA1 [143]. Interestingly, PDIA3 has been postulated to contribute to paclitaxel 
resistance in ovarian cancer cell lines, as a differential expression of PDIA3 in A2780 
and paclitaxel-resistant A2780TC1 cells has been found [144]. Furthermore, PDIA3 is 
highly expressed in the serous ovarian cancer cell line YDOV-139 and may function 
as a potential biomarker for this cancer entity [145]. PDIA3 overexpression was 
associated with low overall survival and recurrence-free survival in cervical cancer 
patients [146].  
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As described above, PDIA1 and PDIA3 carry a CGHC-amino acid motif at their active 
site. Interestingly, it has been shown that cisplatin often binds to a CXXC-motif, for 
example in the Atox1 protein [147]. Furthermore, the CXXC-motif in the metal-binding 
domain of ATP7B was necessary for cisplatin binding [148]. By genetic modification 
of this binding site, resistance against cisplatin in ovarian 2008 cells was reversed 
[148]. CFDA-cisplatin interacts with PDIA1 and PDIA3 implying the possibility that 
cisplatin also interacts with the active sites of PDIA1 and PDIA3, abolishing their 
respective intracellular function and justifying the investigation of these proteins in the 
context of cisplatin resistance [111]. Furthermore, an interference with PDIA1 or 
PDIA3, either genetically or pharmacologically, may mitigate the cellular response to 
ER stress, increasing cisplatin-induced cell death.  
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2 AIM AND OBJECTIVES 
Acquired cisplatin resistance is a major drawback of successful chemotherapy in 
ovarian cancer. Results of recent research proposed intracellular proteins interacting 
with cisplatin as mechanism of resistance. One aim of this project was the 
identification of cytosolic proteins interacting with CFDA-cisplatin, a fluorescent 
cisplatin analogon, in cisplatin-sensitive A2780 and cisplatin-resistant A2780cis 
ovarian cancer cells by 2D gel electrophoresis and subsequent mass spectrometric 
analysis. The following experiments were conducted: 
 Purification of CFDA-cisplatin after synthesis using a semi-preparative HPLC 
for the subsequent determination of proteins interacting with CFDA-cisplatin 
with a high confidence. 
 Sample preparation of A2780 and A2780cis cells treated with CFDA-cisplatin 
for 2D gel electrophoresis. 
 Identification of cytosolic proteins interacting with CFDA-cisplatin by 2D gel 
electrophoresis and ESI-MS (This task was performed by Sandra Kotz at the 
University of Cologne). 
Among the identified proteins were GRP78, PDIA1 and PDIA3 which may be 
involved in cisplatin resistance by acting as a molecular sink for cisplatin or by their 
role in cellular signaling of ER stress response. Another aim of this study was 
therefore the evaluation of these proteins regarding their contribution to cisplatin 
resistance by siRNA-mediated knockdown. Several consecutive experiments after 
knockdown of the mentioned proteins were conducted, such as the MTT assay, an 
apoptosis assay and measurement of DNA platination. Based on these experimetns 
the contribution of the proteins to acquired cisplatin resistance was evaluated. 
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Furthermore, the potential to control cisplatin resistance by a pharmacological 
inhibition was investigated.  
The following objectives were defined: 
 Generation of a transient siRNA-mediated knockdown of GRP78, PDIA1 and 
PDIA3 in A2780 and A2780cis cells. 
 Effect of the respective knockdown on cisplatin cytotoxicity, apoptosis 
induction and DNA platination. 
 Effect of pharmacological inhibition of PDIA1 on cisplatin cytotoxicity, 
apoptosis induction and DNA platination. 
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3 MATERIAL AND METHODS 
3.1 Materials 
3.1.1 Chemicals and reagents 
Acrylamide (30%) Roth GmbH & Co., Karlsruhe 
Actinomycin Sigma-Aldrich GmbH, Steinheim 
AllStars Negative Control siRNA Qiagen, Hilden 
Annexin V Binding Buffer BD Bioscience, Franklin Lakes, USA 
Ammonium persulfate (APS) Roth GmbH & Co., Karlsruhe 
BCA Protein Assay Kit (Novagen) Merck KGaA, Darmstadt 
Bromophenol blue AppliChem GmbH, Darmstadt 
CASY®-Ton, isotonic diluting solution Schärfe System, Reutlingen 
Cisplatin Sigma-Aldrich GmbH, Steinheim 
2-(4-Amidinophenyl)-1H-indole-6-
carboxamidine-dihydrochloride (DAPI) 
Sigma-Aldrich GmbH, Steinheim 
Dimethylformamide (DMF) Sigma-Aldrich GmbH, Steinheim 
Dimethylsulfoxide (DMSO) Sigma-Aldrich GmbH, Steinheim 
Disodium hydrogenphosphate  Honeywell GmbH, Seelze 
Dithiothreitol (DTT) 
ThermoFisher Scientific, Rockford, 
USA 
Ethanol 96 – 100 % (V/V) VWR International, Radnor, USA 
FACS Flow BD Bioscience, Franklin Lakes, USA 
Fetal calf serum (FCS) PAN-Biotech GmbH, Aidenbach 
FITC Annexin V Apoptosis Detection 
Kit with PI 
BioLegend, San Diego, USA 
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FlexiTube siRNA  Qiagen, Hilden 
Glycerol AppliChem GmbH, Darmstadt 
Glycerolphosphat AppliChem GmbH, Darmstadt 
Glycine AppliChem GmbH, Darmstadt 
Isopropanol 100 % (V/V) Merck KGaA, Darmstadt 
K2® Transfectionsystem Biontex Laboratories GmbH, Munich 
Leupeptin hemisulfate Sigma-Aldrich GmbH, Steinheim 
Milk powder Roth GmbH & Co., Karlsruhe 
Methanol Avantor, Deventer, The Netherlands 
MTT AppliChem GmbH, Darmstadt 
Nitric acid 65% (V/V). suprapur Merck KGaA, Darmstadt 
Nuclease 
ThermoFisher Scientific, Rockford, 
USA 
Penicillin streptomycin solution  PAN-Biotech GmbH, Aidenbach 
Pepstatin A Sigma-Aldrich GmbH, Steinheim 
PeqGOLD Protein Marker V PEQLAB GmbH, Erlangen 
Pierce™ ECL Substrate 
ThermoFisher Scientific, Rockford, 
USA 
Potassium chloride Sigma-Aldrich GmbH, Steinheim 
Potassium dihydrogen phosphate AppliChem GmbH, Darmstadt 
Propynoic acid carbamoyl methyl 
amide 31 (PACMA31) 
Merck Millipore, Darmstadt 
RNAse-free water Qiagen, Hilden 
RPMI 1640 medium PAN-Biotech GmbH, AIdenbach 
Sodium azide Merck KGaA, Darmstadt 
Sodium chloride Th. Geyer GmbH, Renningen 
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Sodium dodecyl phsphate (SDS) Roth GmbH & Co., Karlsruhe 
Sodium deoxycholate  AppliChem GmbH, Darmstadt 
Sodium hydroxide (NaOH) Sigma-Aldrich GmbH, Steinheim 
Tetramethylethylendiamine (TEMED) AppliChem GmbH, Darmstadt 
Tergitol solution Sigma-Aldrich GmbH, Steinheim 
Tris(hydroxymethyl)aminomethane AppliChem GmbH, Darmstadt 
Triton®X-100 AppliChem GmbH, Darmstadt 
Trypsin-EDTA solution Sigma-Aldrich GmbH, Steinheim 
Tween®-20 AppliChem GmbH, Darmstadt 
Ultrapure water  
Obtained by Purelab Plus™ system, 
Elga Labwater, Celle 
3.1.2 Buffers and solutions 
Phosphate buffered saline (PBS) 
 
 
NaCl 8.0 g 
 
KCl 0.2 g 
 
Na2HPO4 x 2 H2O  1.4 g 
 
Potassium dihydrogen phosphate  0.2 g 
 
Ultrapure water  ad 1000.0 mL 
 
pH adjusted to 7.4 using sodium hydroxide or hydrochloric acid 
   Cisplatin stock solution [5 mM] 
 
 
Cisplatin  1.5 mg 
 
Sodium chloride solution 0.9%  1.0 mL 
  
CFDA-cisplatin stock solution [50 mM] 
 
CFDA-cisplatin 39.88 mg 
 
DMF 1.0 mL 
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PACMA31 stock solution [58 mM] 
 
PACMA31 25 mg 
 
DMSO 1.0 mL 
   3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution 
[5 mg/mL] 
 
MTT  10 mg 
 
PBS  2.0 mL 
   Radioimmunoprecipitation assay buffer (RIPA) 
 
 
Tris-HCl 394 mg 
 
NaCl 880 mg 
 
Triton X100 1 mL 
 
Sodium deoxycholate 1 g 
 
EDTA 29.2 mg 
 
Ultrapure water ad 100 mL 
 
pH adjusted to 7.4 using sodium hydroxide 
 
   Cell lysis buffer (CLB IV) 
 
HEPES  0.238 g 
 
KCl 0.298 g 
 
MgCl2 
0.029 g 
 
Glycerine 5 mL 
 
NP-40 0.5 mL 
 
Ultrapure water ad 100 mL 
 
pH adjusted to 7.4 using sodium hydroxide 
 
 DAPI stock solution [1 mg/mL] 
 
 
DAPI  1 mg 
 
Methanol  1000 μL 
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DAPI working solution [5 μg/mL] 
 
 
DAPI stock solution  5 μL 
 
Ultrapure water  ad 1000 μL 
   siRNA solution [10 µM] 
 
siRNA (against GRP78, PDIA1, PDIA3 or 
negative control) 5 nmol 
 
RNAse free water 500 µL 
   Transfection solution for 2 wells of a 6 well plate 
 
RPMI 1640 medium 125 µL 
 
K2® reagent 13.5 µL 
 
RPMI 1640 medium 125 µL 
 
siRNA [10 µM] 10 µL 
 
Mix both solutions 
 
   SDS page and protein immunoblotting 
 Ammonium persulfate (APS) solution [10%] 
 
 
APS  100 mg 
 
Ultrapure water ad 1000.0 μL 
   Dithiothreitol (DTT) solution [3.2 M] 
 
 
DTT  49.4 mg
 
Ultrapure water  ad 1000.0 μL 
   Loading buffer 
 
 
Stacking gel buffer  1.75 mL
 
Glycerol  1.5 mL 
 
Sodium dodecyl sulfate solution (see below)  5 mL 
 
Bromophenol blue solution*  1.25 mL 
 
* Saturated bromophenol blue solution in ultrapure water 
containing 0.1% ethanol. 
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Sodium dodecyl sulfate (SDS) solution [10%] 
 
 
SDS  1.0 g 
 
Ultrapure water  ad 10.0 mL 
   Stacking gel buffer (pH 6.8) 
 
 
Tris base  12.11 g
 
Ultrapure water  ad 100.0 mL 
 
pH adjusted to 6.8 
  
Separating gel buffer (pH 8.8) 
 
 
Tris base  12.11 g
 
Ultrapure water  ad 100.0 mL 
 
pH adjusted to 8.8 using hydrochloric acid 
 
   Western Blot 
 Tris-buffered saline (TBS) 
 
 
Sodium chloride  4 g
 
Tris base  0.6 g 
 
Ultrapure water  ad 500.0 mL 
 
pH adjusted to 7.3 using hydrochloric acid 
 
 Tris-buffered saline with Tween®-20 (TBS-T) solution 
 
 
Tween®-20  1.6 mL
 
TBS  ad 800.0 mL 
   Blocking solution 
 
 
Milk powder  5 g
 
TBS-T solution  ad 100.0 mL 
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Transfer buffer 
 
 
Glycine  14.4 g
 
Tris base  3 g 
 
Ultrapure water  ad 800.0 mL 
 
pH adjusted to 8.2 to 8.4 
 
   Primary antibody dilution 
 
 
Sodium azide  10 mg
 
BSA  500 mg 
 
antibody (goat polyclonal IgG)  as required 
 
TBS-T solution 10.0 mL 
 Secondary anti-rabbit antibody solution  
 
 
Milk powder  0.5 g
 
Anti-goat IgG horseradish peroxidase-
conjugated antibody  as required 
 
TBS-T solution  10.0 mL 
  
3.1.3 Equipment 
Axiovert® 25 inverted microscope  Carl Zeiss AG, Oberkochen 
Beckman Microfuge® Lite  Beckman-Coulter, Fullerton, USA 
Casy®1 cell counter, Modell TT  Schärfe System, Reutlingen 
Centrifuge Universal 32R  Hettich GmbH & Co. KG, Tuttlingen 
Centrifuge Mikro 200R  Hettich GmbH & Co. KG, Tuttlingen 
Colibri® microvolume spectrometer Titertek-Berthold, Pforzheim 
Degasser, Degasys® Ultimate Sanwa Tshusho Co., Japan 
Gel electrophoresis Cleaver Scientific Ltd., Warwickshire, 
UK 
FACSCalibur®, Flow cytometer BD Bioscience, Franklin Lakes, USA 
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Fluoroskan Ascent® microplate 
reader  
Thermo Fisher Scientific, Langenselbold 
ICP-MS Varian 820  Varian, Darmstadt 
Incubator Thermo  Thermo Electron GmbH, Dreieich 
InoLab® pH level 2 pH Meter  WTW GmbH, Weilheim 
Kern 770 analytical balance  Kern & Sohn GmbH, Balingen-
Frommern 
Kern EW analytical balance  Kern & Sohn GmbH, Balingen-
Frommern 
Laminar air flow work bench  Heraeus Holding GmbH, Hanau 
MT Classic AB135-S analytical 
balance 
Mettler-Toledo GmbH, Giessen 
Multiskan Ascent® microplate 
reader 
Thermo Electron GmbH, Dreieich 
Multiskan EX® microplate reader Thermo Electron GmbH, Dreieich 
Nikon A1 Eclipse Ti® confocal 
microscope  
Nikon, Kingston, UK 
Purelab PlusTM system  ELGA LabWater, Celle 
Shaker KS 15 control  Edmund Bühler GmbH, Hechingen 
Sonicator Bandelin 
HD2070/UW2070 
Bandelin electronic GmbH, Berlin 
System Gold® Autosampler 507 Beckman Coulter, Krefeld 
System Gold® Detector 168 Beckman Coulter, Krefeld 
System Gold® Pump 126 Beckman Coulter, Krefeld 
Ultrasonic bath Sonorex® Super 
RK 103 H  
Bandelin electronic GmbH, Berlin 
Versa Doc™ Imaging System 5000 Bio-Rad Laboratories GmbH, Munich 
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3.1.4 Consumables 
Blotting paper, 7 x 10 cm Sigma-Aldrich GmbH, Steinheim 
Casy® tubes  Schärfe System, Reutlingen 
Cell culture flasks 25, 75, 175 cm2  Sarstedt AG & Co., Nümbrecht 
Cell scraper  Sarstedt AG & Co., Nümbrecht 
Conical centrifuge tubes 15, 50 mL  Sarstedt AG & Co., Nümbrecht 
Cover slips (round, square) Carl Roth GmbH & Co., Karlsruhe 
Cryovials  Sarstedt AG & Co., Nümbrecht 
Disposable syringe (10 mL) B. Braun Melsungen AG, Melsungen 
Glass pipettes  Labomedic GmbH, Bonn 
Microscope slides  Carl Roth GmbH & Co., Karlsruhe 
Pasteur pipettes Brand GmbH & Co., Wertheim 
Petri dishes Greiner Labortechnik, Frickenhausen 
Pipette tips  Mettler-Toledo GmbH, Giessen 
Polyvinylidene fluoride membrane  Carl Roth GmbH & Co.KG, Karlsruhe 
peqGold Tissue DNA Mini Kit  peqlab Biotechnologie GmbH, Erlangen 
Reaction tubes (0.5, 1.5, 2 mL)  Greiner Labortechnik, Frickenhausen 
Sample vials (2 mL, conical)  Varian GmbH, Darmstadt 
Tissue culture plates, 96 wells  Sarstedt AG & Co., Nümbrecht 
Tissue culture plates, 6 wells  Sarstedt AG & Co., Nümbrecht 
3.1.5 Software 
Ascent Software (Multiskan Ex®) Thermo Electron GmbH, Dreieich 
FlowJo® V10 Tree Star Inc., Ashland, USA 
GraphPad Prism® 6.0 GraphPad Software, San Diego, USA 
34 MATERIAL AND METHODS 
 
Image Lab® 5.1 Bio-Rad Laboratorien, Munich 
Microsoft Excel® 2007 Microsoft Corporation, Redmond, USA 
System Gold® Beckman Coulter, Krefeld 
3.2 HPLC purification of CFDA-cisplatin 
Reversed-phase high-performance liquid chromatography (RP-HPLC) allows the 
separation of different chemical entities according to their hydrophobicity/polarity. 
Semi-preparative RP-HPLC can be used to purify compounds of interest after 
synthesis of small scale batches. A gradient method was optimized on a Beckman 
Coulter System Gold® HPLC in order to achieve a high purity for CFDA-cisplatin after 
the chemical synthesis. As solvent A ultrapure water was used without further 
additives. Solvent B was HPLC grade acetonitrile without any further additives as 
well. The final gradient method used is shown in Table 1. The method was 
established on an analytical column (Nucleodur® C18 HTec, 5 µM, 250x4 mm) and 
then transferred to a semi-preparative column (Varioprep Nucleodur® C18 HTec, 
5 µM, 250x10 mm). 
Table 1 RP-HPLC time program for the purification of CFDA-cisplatin. 
% B 
Duration 
[min] 
Time 
[min] 
20 5 0 
30 5 5 
60 20 10 
95 2 30 
95 5 32 
20 2 37 
20 5 39 
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The mobile phase flow rate was 1.0 mL/min for the analytical column and 2.7 mL/min 
for the semi-preparative column. The mobile phases were degassed by sparging with 
helium followed by an in-line degasser (Degasys®) during the HPLC runs. The 
injection volume was 40 µL in ‘microlitre pickup mode’, in order to minimize the 
sample loss. The chromatograms were recorded with a diode array detector from 220 
to 680 nm wavelength. The fraction of interest was collected and dried in vacuum. 
3.3 Cell culture 
3.3.1 Cell lines and cultivation 
The ovarian carcinoma cell line A2780 and the cisplatin-resistant variant A2780cis 
(European Collection of Cell Cultures, United Kingdom) were cultivated as 
monolayers in RPMI-1640® medium supplemented with 10% fetal calf serum (FCS), 
100 U/mL penicillin and 0.1 mg/mL streptomycin (37 °C, 5% CO2). Cells were 
cultivated to about 90% confluence and then sub-cultivated or used in experiments. 
Backups of each cell line suspended in FCS containing 10% DMSO were stored in 
liquid nitrogen. After using cells over a period of at most 12 passages they were 
discarded and a new backup was thawed. The level of resistance of the resistant 
variants was monitored by the MTT-based cytotoxicity assay (see 3.5). If a distinct 
number of cells was needed for an experiment, cells in a cell suspension were 
counted by electronic pulse area analysis using a Casy®1 cell counter. Distribution of 
cell volume and cell aggregation were assessed at the same time. 
3.3.2 Mycoplasma test  
A challenge in cell culture is a possible contamination of cells with mycoplasma 
bacteria that may influence research results. Mycoplasma can grow on cultivated 
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mammalian cells and are resistant to common antibiotics. Cells were regularly 
screened for mycoplasma infections using 2-(4-amidinophenyl)-1H-indole-6-
carboxamidine-dihydrochloride (DAPI). DAPI binds to cellular DNA and can be 
detected by fluorescence microscopy. 
Cells were seeded on microscope slides in a petri dish. After two to three days the 
medium was removed and the slide washed with 5 mL of cold PBS. Then, cells were 
incubated with 80 μL of DAPI working solution in 2 mL methanol for 5 min. 
Subsequently, the slide was washed with 2 mL methanol and dried in the dark. Cover 
slips were fixed on the slides using mounting medium. Cells were analyzed using a 
Nikon Eclipse Ti® fluorescence microscope. Positively stained cells show a blue 
shade surrounding cells, accounting for stained mycoplasma DNA. No mycoplasma 
contaminations were detected. 
3.4 Sample preparation and cell fractionation 
Two-dimensional gel electrophoresis (2DE) is a powerful tool for the separation of 
complex protein mixtures enabling the separation and visualisation of hundreds to 
thousands of proteins. In order to reduce the sample complexity for the analysis cell 
lysates were fractioned into three main fractions (nuclear, mitochondrial, cytosolic). 
The cytosolic fraction was used for the 2DE experiments performed by Sandra Kotz 
(University of Cologne). 
All steps of the fractionation were performed on ice and all centrifugation steps were 
done at 4°C if not stated otherwise. 
After washing with PBS, cells were harvested in 1 mL PBS using a cell scraper. After 
centrifugation at 160 g for 4 min, the PBS was discarded and the pellet was dissolved 
in lysis buffer supplemented with pepstatin A (2 µM) and leupeptin (1 µM). After 
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swelling on ice for 5 min, the cell suspension was sonicated three times at 25% 
power with intermittent 30 sec breaks using an ultrasonic homogenizer (Sonicator 
Bandelin HD2070/UW2070). The lysate was transferred to 1.5 mL reaction tubes and 
centrifuged at 700 g for 15 min. The pellet was labeled ‘nuclear fraction’ (N). The 
supernatant was transferred to a new reaction tube and centrifuged at 15000 g for 
20 min. The pellet was labeled ‘mitochondrial fraction’ (M). The final supernatant was 
transferred to a new reaction tube and labeled ‘cytosolic fraction’ (C). 
The efficiency of fractionation was analyzed by detection of marker proteins using 
Western Blot (see 3.8). For the nuclear fraction, an antibody against the nuclear 
matrix protein lamin B1 (GTX103292) was used. The mitochondrial fraction was 
analyzed with an antibody against cytochrome c oxidase subunit IV isoform 1 
(COX IV) (GTX101499). Cytochrome c oxidase (COX) is the terminal enzyme of the 
mitochondrial respiratory chain. GAPDH (GTX100118) was used as an indicator for 
the purity of the cytosolic fraction. Cross-contamination of the fractions was assumed 
in case that a marker protein was detected in the wrong fraction. 
3.5 Cytotoxicity assay 
Cytotoxic properties of compounds and in consequence the sensitivity of cells 
towards these compounds were assessed using an MTT assay. The assay is based 
on the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT), a yellow tetrazole, to a purple formazan by mitochondrial dehydrogenases of 
living cells (see Figure 10). 
Cells were seeded in 96-well plates at a density of 1 x 104 cells per well (A2780, 
A2780cis) in 90 μL cell culture medium and allowed to attach overnight (37 °C, 
5% CO2). As protection against evaporation the outer wells were filled with PBS only. 
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The following day 10 μL of cisplatin in increasing concentrations were added to each 
well. Each concentration was tested in triplicate. The plates were incubated for 71 h. 
Then 20 μL of MTT in PBS (5 mg/mL) were added and the plates were placed in the 
incubator again for 1 h. The supernatant was discarded. Cells and formed formazan 
crystals were lysed by addition of 100 μL DMSO. The plates were shaken and UV 
absorbance at 570 nm with background subtraction at 690 nm was measured using a 
Multiskan Ascent® microtiter plate reader. 
 
Figure 10 Reduction of MTT by dehydrogenases. 
The procedure described was adapted from Mueller et al. [149] but slightly modified 
(cell and formazan lysis with DMSO instead of 1:1 isopropanol and 1 M HCl as 
described by Alley et al. [150]). Dose-effect curves were calculated by non-linear 
regression using the software GraphPad Prism® with a variable slope model 
(settings: no comparison, constraint: ‘BOTTOM must be greater than 0.0‘, no 
weighting, consider each replicate Y value as an individual point). Effective 
concentrations (EC50 , EC10: concentrations that provoke 50% or 10% of the maximal 
response, respectively) were calculated based on the following equation: 
Equation 1                -      
    ((LogEC50-x)    illSlope) 
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The resistance factor (RF) was calculated by division of the EC50 of resistant cells by 
the EC50 value of sensitive cells: 
Equation 2         
EC50          
EC50          
 
 
3.6 Protein quantification 
In order to load equal amounts of protein for the Western Blot analysis, the protein 
concentration of the samples was assessed using the bicinchoninic assay. The assay 
is based on the reduction of Cu2+ to Cu+ by proteins under alkaline conditions. Two 
molecules of bicinchoninic acid (BCA) react with one molecule of Cu+ forming a 
purple chelate complex. The absorbance of the purple chelate complex at 562 nm 
was determined using a UV microtiter plate reader. Protein concentration was 
calculated using a calibration curve. 
3.6.1 Standard solutions and quality control samples 
Standard solutions and quality control (QC) samples were prepared by diluting a 
2 mg/mL stock solution of bovine serum albumin (BSA) provided by the manufacturer 
according to Table 2. 
X concentration 
Y absorption 
Bottom value for Y for the minimal curve asymptote 
Top value for Y for the maximal curve asymptote 
LogEC50 logarithm of drug concentration producing half maximal response 
HillSlope steepness of concentration response curve 
EC50 resistant EC50 value determined for A2780cis cells 
EC50 sensitive EC50 value determined for A2780 cells 
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Table 2 Standard solutions and quality controls for protein quantification. 
 
Volume BSA 
stock solution 
[µL] 
Volume water 
[µL] 
Protein concentration 
[µg/mL] 
Standard solutions 
S1 50 1950 50 
S2 75 1925 75 
S3 100 1900 100 
S4 200 1800 200 
S5 300 1700 300 
S6 400 1600 400 
Quality control samples 
Q1 150 1850 150 
Q2 250 1750 250 
Q3 350 1650 350 
3.6.2 Sample preparation 
Samples were analyzed according to the manufacturer’s protocol. After dilution of 
samples to fit into the calibration range, 25 µL of standard solution, quality control, 
and sample were transferred to a 96-well plate. Then a mixture of 50 parts BCA 
working reagent A (containing BCA) and 1 part BCA working reagent B (containing 
CuSO4) was prepared. 200 μL of the mixture was added to each well and the plate 
was incubated for 15 min at 60 °C. After 5 min of cooling to room temperature the UV 
absorbance at 570 nm was determined using a Multiskan Ascent® microtiter plate 
reader. Linear regression of standard solutions was performed using Microsoft Excel® 
2007 and sample concentrations were calculated from the calibration curve. The 
calibration was considered valid if at least four of the standard solutions did not 
deviate more than 15% from the nominal value (20% at the lower limit of 
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quantification) and two of three QC samples did not deviate more than 15% of the 
nominal value. 
3.7 RNA interference 
3.7.1 Background 
In order to transiently reduce the expression of a target protein, one possibility is 
silencing the gene of interest by RNA interference (RNAi). A small interference RNA 
(siRNA) molecule (double-stranded RNA with a length of 21 to 25 base pairs) is 
introduced into the cell via lipofection. Here, cationic polymers form complexes with 
the negatively charged siRNA, which then can penetrate into the cell via endocytosis. 
Endosomes inside the cell release the siRNA. After integration in the RNA-induced 
silencing complex (RISC) the siRNA hybridizes with the corresponding mRNA. This 
activates a degradation process of the mRNA by nucleases, which ultimately inhibits 
translation of the respective protein. 
3.7.2 Optimization of siRNA conditions 
The transfection conditions were evaluated and optimized using fluorescent siRNA 
(siGLO®). A2780 and A2780cis cells were seeded in 96-well plates at 1 x 104, 2 x 104 
and 3 x 104 cells per well in 100 µL medium without antibiotics. After the attachment 
of cells overnight, 0.25, 0.5, and 1.0 µL of the K2® and 0.1, 0.2, and 0.3 µL of the 
Jetprime® transfection reagent were used to transfect 50 nM of siGLO® siRNA. After 
24 h, the medium was discarded and the wells were washed with PBS twice. Then, 
the fluorescence was measured on a Flouroskan® at 485 nm and 538 nm. 
Afterwards, cell viability was assessed by the MTT assay (Chapter 3.5). In control 
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experiments, cells were incubated with the transfection reagent without siRNA. For 
the evaluation of results, the fluorescence of the control cells was defined as 100%. 
3.7.3 SiRNA-mediated transient knockdown 
A2780 and A2780cis cells were seeded in 6-well plates at 0.5 x 106 cells per well in 
1 mL medium without antibiotics and incubated for 24 h. The siRNA directed against 
the respective protein was introduced into the cell via lipofection (see Table 3). In 
order to evaluate the influence of the transfection procedure on protein expression, a 
negative knockdown with a scrambled siRNA (not coding for any protein) was 
performed. For 2 wells of a 6-well plate 10 µL of the respective siRNA (10 µM) were 
diluted with 125 µL of medium. At the same time 13.5 µL of K2® transfection reagent 
were mixed with 125 µL of medium. Both solutions were mixed by gentle pipetting 
and incubated for 15 min at room temperature. Then, 125 µL of the mixture were 
added to each well and plates were gently swayed. After 24 h the medium was 
changed for full medium and cells were incubated for another 48 h. Efficiency of 
knockdown was assessed by Western Blot (see 3.8). 
Table 3 Base sequences of the siRNA used. 
Protein Target Sequence Sense sequence Antisense sequence 
GRP78 
5’-
TAGGGTGTGTGTTC
ACCTTCA-3’ 
5’-
GGGUGUGUGUUCA
CCUUCATT-3’ 
5’-
UGAAGGUGAACACA
CACCCTA-3’ 
PDIA3 
5’-
AAGGAATAGTCCCA
TTAGCAA-3’ 
5’-
GGAAUAGUCCCAUU
AGCAATT-3’ 
5’-
UUGCUAAUGGGAC
UAUUCCTT-3’ 
PDIA1 
5’-
CAGGACGGTCATTG
ATTACAA-3’ 
5’-
GGACGGUCAUUGA
UUACAATT-3’ 
5’-
UUGUAAUCAAUGAC
CGUCCTG-3’ 
Negative 
control 
scrambled sequence   
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3.8 SDS Page and Western Blot 
Protein expression was analyzed by Western Blot. After the separation of proteins by 
SDS gel electrophoresis they were transferred to a polyvinylidene fluoride (PVDF) 
membrane. The detection of proteins was performed by incubation of membranes 
with antibodies against specific proteins (primary antibodies) followed by incubation 
with antibodies conjugated with horseradish peroxidase (HRP) (secondary antibody). 
Proteins were detected after incubation of the membrane with luminol. HRP oxidizes 
luminol which then shows a chemiluminescent signal. Protein expression in 
experiments was normalized to the expression of GAPDH as a housekeeping 
protein. 
3.8.1 Sample preparation  
Cells were seeded in 6-well plates at densities of 2.5 x 105 – 5 x 105 cells per well, 
depending on the incubation time (24 to 48 h). After treatment cells were washed 
with ice-cold PBS once. Radioimmunoprecipitation (RIPA) buffer was added leading 
to cell lysis and cells were additionally scraped of the surface with a cell scraper. The 
lysates were transferred to reaction tubes and incubated on ice for 15 min. After 
centrifugation (15000 g, 4 °C, 5 min) the supernatant was used for protein 
quantification and Western Blot analysis. 
3.8.2 Gel electrophoresis and Western Blot  
Separation of proteins according to size was performed by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE). Separating and stacking 
polyacrylamide gels were prepared according to Table 4. The separating gel with fix 
acrylamide percentages of 10 or 12% was poured into the cassette and overlayed 
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with isopropyl alcohol. After 15 min isopropyl alcohol was removed, the stacking gel 
was added on top and wells for sample application were prepared using a comb. 
After 30 min the fixture containing the gels was placed in the electrophoresis 
chamber. Electrophoresis buffer was added until the gels were completely covered. 
The comb was removed and the wells rinsed with buffer. Samples were diluted to a 
concentration of 10 to 20 μg protein per 20 μL with the loading buffer, which was 
supplemented with 5% dithiothreitol (DTT) solution. After denaturation of the samples 
for 15 min at 60 °C, samples as well as a protein marker were pipetted into the wells 
of the gel. Afterwards the proteins were separated at 200 V for approximately 50 min 
or until the sample front reached the end of the gel. PVDF membranes were 
activated with methanol for 20 sec and shaken for 5 min in transfer buffer for 
equilibration. Afterwards the gel and the membrane were clamped tightly in a fixture. 
By applying an electric current (100 V, 350 mA, 60 min) the proteins were transferred 
to the PVDF membrane. In order to visualize more than one protein band on a single 
blot, the membrane was cut according to protein size in reference to the protein 
marker. The membranes were subsequently treated with the respective antibodies. 
Table 4 Preparation of separating and stacking gel for Western Blot. 
 
Separating gel 
10% 
Separating gel 
12% 
Stacking gel 
Acrylamide [30%] 3.30 mL 3.97 mL 833 µL 
Separating gel buffer 3.75 mL 3.75 mL - 
Stacking gel buffer - - 625 µL 
Ultrapure water 2.76 mL 2.10 mL 3.445 mL 
SDS [10%] 100 µL 100 µL 50 µL 
TEMED* 18 µL 18 µL 5 µL 
Ammonium 
peroxodisulfate [10%]* 
70 µL 70 µL 20.8 µL 
*Addition shortly before casting the gel in order to initiate polymerization 
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3.8.3 Visualization of proteins  
To minimize unspecific binding of antibodies, membranes were blocked with 5% skim 
milk solution for 1 h. Subsequently, the membrane was washed three times for 
10 min with TBS-T solution. The primary antibody against the respective protein was 
added and the membrane was incubated overnight at 4 °C. The following morning 
the antibody solution was removed from the membrane. By conservation with 0.1% 
sodium azide, the primary antibody solution was reused several times. The 
membrane was washed three times for 10 min with TBS-T solution. Subsequently, it 
was incubated for 90 min with the respective secondary antibody conjugated to HRP. 
The solution was removed and discarded. The last washing step consisted of two 
times washing for 10 min with TBS-T solution. For visualization Pierce™ ECL 
Western Blotting Substrate was used according to the manufacturer’s protocol and 
1000 μL of the substrate were evenly distributed onto the membrane. After 2 min of 
incubation, the chemiluminescent signal was detected with the ChemiDoc™ XRS 
Imaging System producing a digital image, which was densitometrically quantified 
with the Image Lab® software. 
3.9 Apoptosis analysis 
Apoptosis, or programmed cell death, is a regulated cellular process intended for the 
maintenance of tissue homeostasis by removal of unwanted cells. It is initiated 
following cellular stress, which may be inflicted e.g. by DNA damage following a 
cisplatin treatment. An intracellular proteolytic cascade of procaspases and caspases 
leads to the cleavage of key proteins in the cell. This enforces the complete 
disassembly of the cell.  
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The cell membrane phospholipid phosphatidylserine is under normal cellular 
circumstances located on the cytoplasmic side of the membrane. At the onset of 
apoptosis phosphatidylserine translocates to the external leaflet of the membrane. 
Here, the phospholipid-binding protein Annexin V can specifically recognize and bind 
to phosphatidylserine with a high affinity. By labeling Annexin V with a fluorochrome 
such as fluorescein isothiocyanate (FITC) it is possible to identify early apoptotic cells 
using flow cytometry. An additional DNA dye, which is not cell membrane permeable, 
such as propidium iodide, permits the differentiation of early and late apoptotic cells. 
Early apoptotic cells still exhibit cell membrane integrity thus hindering the binding of 
propidium iodide to the DNA. In late stages of apoptosis, propidium iodide can 
penetrate the cell and a positive staining can be monitored. 
Apoptosis was analyzed using the FITC Annexin V Apoptosis Detection Kit with PI® 
(BioLegend, San Diego, USA) according to the procedure suggested by the 
manufacturer. Cells were seeded in 6-well plates at a density of 0.5 x 106 cells per 
well. After 24 h the knockdown was performed as described in section 3.7. The next 
day, cells were treated with 10 µM cisplatin for 24 h. Finally, the medium was 
collected and cells were harvested by addition of 200 µL trypsin. Cells were washed 
with cold PBS twice and centrifuged at 1000 g for 5 min. The cell pellet was 
resuspended in Annexin V binding buffer® at a concentration of 1 x 106 cells/mL. 
After addition of 5 µL FITC Annexin V solution and 10 µL propidium iodide (PI) 
solution cells were gently vortexed and stained for 15 min at room temperature in the 
dark. Cells were diluted by addition of 400 µL of Annexin V binding buffer® and finally 
analyzed by flow cytometry within 1 h (FACScalibur®, BD Biosciences, San Jose, 
USA). Intact cells were gated with FlowJo® v10 (TreeStar, Ashland, USA) in the 
forward/side scatter to exclude small debris. Annexin V FITC-positive and propidium 
MATERIAL AND METHODS 47 
 
iodide-negative (Annexin FITC-V (+)/PI (-)) cells were gated to identify the early 
apoptotic (EA) population, Annexin FITC-V (+)/PI (+) cells to identify the late 
apoptotic (LA) population. 
3.10 DNA platination 
Binding of cisplatin to nuclear DNA is discussed as crucial step in the mechanism of 
action of cisplatin. DNA platination can be used as a surrogate measure for the 
therapeutic effect of cisplatin. In order to analyze the DNA platination cells were 
treated with cisplatin and the nuclear DNA was isolated. After quantification and 
digestion of DNA in nitric acid, platinum concentration was measured by inductively 
coupled plasma mass spectrometry (ICP-MS). 
Cells were seeded in 6 well plates at a density of 0.5 x 106 cells per well and allowed 
to attach overnight. After knockdown of the respective protein (see 3.7) cells were 
treated for 4 h with 100 µM or for 24 h with 5 µM cisplatin. After washing with PBS, 
nuclear DNA was extracted using the peqGOLD Tissue DNA Mini Kit (PEQlab, 
Erlangen). The procedure is based on a solid phase extraction of DNA after cell lysis. 
After medium aspiration, cells were washed with PBS. Then, 400 µL of DNA lysis 
buffer T, supplemented with 20 µL proteinase K and 15 µL RNAse A were added to 
the wells. Cells were additionally detached with a cell scraper. Samples were 
vortexed for 10 sec and then incubated for 15 min at 50 °C with three intermittent 
vortexing steps for 30 sec. DNA binding buffer was added to the samples and 
thoroughly mixed. Samples were loaded on the PerfectBind DNA column and 
centrifuged for 1 min at 10000 g. The supernatant was discarded. Samples were 
washed twice with 650 µL DNA washing buffer, followed by subsequent 
centrifugation at 10000 g for 1 min. After a 2 min drying phase of the column at 
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10000 g, samples were incubated with 100 µL elution buffer for 3 min. Next, samples 
were eluted by centrifugation at 6.000 g for 1 min. The final DNA concentration was 
determined in 1 µL sample on a Colibri® microvolume spectrometer (Titertek-
Berthold, Pforzheim) based on UV wavelength. The purity of DNA was assessed by 
the absorption ratio at 260 and 280 nm (A260/280). 
Samples were digested with 300 µL of 1% nitric acid at 70 °C for 24 h. Platinum 
content was determined on a Varian 820 ICP-MS as previously described [151]. In 
brief, for determination by ICP-MS samples are ionized in inductively-coupled 
plasma. The ions of interest are separated and quantified by a mass spectrometer.  
Table 5  Accuracy and precision of DNA platination measurements. 
 Concentration [ng/L] 
 50 500 1000 2000 
Day 1 49.6 507.6 1031.5 2002.7 
 45.9 513.0 991.3 2139.1 
Day 2 54.6 559.0 916.6 1880.4 
 42.3 470.5 927.9 1877.5 
Day 3 49.0 512.3 1030.8 1944.4 
 47.4 561.1 1008.6 1758.2 
Mean 48.2 520.6 984.4 1933.7 
SD 4.1 34.4 50.6 129.5 
RSD [%] 8.53 6.61 5.14 6.70 
RE [%] -3.7 4.1 -1.6 -3.3 
 
Each ICP-MS analysis resulted from five replicate measurements consisting of 20 
scans of the relevant platinum isotopes. For platinum quantification the platinum 
isotope 195 (195Pt) was chosen. Quality control samples and an internal standard 
were used to ensure the accuracy (by calculation of the relative error, Equation 6), 
and precision (by calculation of the relative standard deviation, Equation 7) of the 
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measurements (Table 5) which were below the threshold of <15%. The results were 
finally expressed as mass of platinum per mass of DNA (Pt/DNA [pg/µg]). 
3.11 Combination index 
Drug combinations may affect multiple targets of a disease, increasing the efficacy of 
the therapeutic intervention, decreasing the emergence of resistance or minimizing 
drug toxicity. In order to evaluate the possible benefit of a combination of cisplatin 
with PACMA31 (Figure 9), the combination index (CI) was calculated with the 
CompuSyn® software (ComboSyn, Paragon, NJ, USA) as described by Chou [152]. 
When two drugs are combined and subjected to serial dilutions, the combined 
mixture behaves like a third drug for the dose-effect relationship. The calculation is 
based upon the multiple drug-effect equation introduced by Chou and Talalay in 1984 
[153]: 
Equation 3        
    
     
  
    
     
 
(D)1: Concentration of drug 1 in combination with drug 2 that inhibits a system by x% 
(D)2: Concentration of drug 2 in combination with drug 1 that inhibits a system by x% 
(Dx)1: Drug 1 alone that inhibits a system by x% 
(Dx)2: Drug 2 alone that inhibits a system by x% 
CI values of < 1, = 1, or > 1 were considered as synergism, additivity and 
antagonism, respectively. 
The result describes the effect of the substances in regard to synergism or 
antagonism. How this effect is achieved or on what mechanism it is based, needs to 
be investigated by other experiments. 
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Cells were seeded in 96-well plates and treated with 10, 20, 40, 60, 80, 100, 200, 
400 and 800% of the previously determined EC50 of cisplatin, of PACMA31 or a fix 
combination of cisplatin and PACMA31 (see Table 6). The ratio of cisplatin to 
PACMA31 in the combination was 5.7 for A2780 and 21.3 for A2780cis cells. After 
72 h, the interaction was assessed by the MTT assay as described in 3.5. 
Table 6 Cisplatin and PACMA31 concentrations used for the determination of the 
combination index in A2780 and A2780cis cells. Substances were tested alone 
and as a fix combination at the indicated concentrations. 
Concentration 
[% of EC50] 
Concentration [µM] 
 A2780 cells A2780cis cells 
 Cisplatin PACMA31 Cisplatin PACMA31 
10 0.21 0.037 0.98 0.046 
20 0.42 0.074 1.96 0.092 
40 0.84 0.148 3.92 0.184 
60 1.26 0.222 5.88 0.276 
80 1.68 0.296 7.84 0.368 
100 2.10 0.370 9.80 0.460 
200 4.20 0.740 19.6 0.920 
400 8.40 1.48 39.2 1.84 
800 16.8 2.96 78.4 3.68 
3.12 Statistical analysis 
The mean of at least three independent experiments (biological replicates) was 
calculated and the result presented as mean ( ) and standard deviation (SD). 
Equation 4     
n
x
x
n
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  
Equation 5      
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 :   arithmetic mean 
xi:   individual measured values 
SD:  standard deviation 
n:   number of measurements 
The accuracy and precision of measurement was described by the relative error 
(RE, Equation 6) and the relative standard deviaton (RSD, Equation 7) 
Equation 6  
µ
100µ)x(
RE[%]

  
Equation 7  
x
100SD
RSD[%]

  
 :   arithmetic mean 
µ   nominal value 
SD:  standard deviation 
EC50 data describing the cytotoxic effect were assumed to be log-normally distributed 
[154]. Therefore, the negative logarithm of the EC50 (pEC50) value was calculated. 
Afterwards, mean and standard error of the mean (SEM) were determined.  
Equation 8      SEM   SD
   
Statistical comparisons between groups in siRNA experiments were carried out using 
a one-way analysis of variance (ANOVA). If a significant difference was found the 
Holm-Sidak post-test was used to determine which means differed.  
Differences were considered statistically significant in the case of p < 0.05, otherwise 
no statistically significance was assumed. 
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4 RESULTS 
4.1 Establishing a method for the purification of CFDA-cisplatin 
While performing the first experiments with CFDA-cisplatin (Figure 5) it became 
obvious, that after the synthesis of CFDA-cisplatin using the published method of 
Molenaar et al. [109], unreacted CFDA-NHS ester (Figure 11 A) and different other 
impurities were present in the final product. As these impurities may have led to false 
positive signals in subsequent experiments, purification of the synthesis product was 
considered mandatory. As other methods of purification, such as recrystallization, 
were unsuccessful, a HPLC method for purification of CFDA-cisplatin was 
established. 
 
Figure 11 Chemical structure of (A) CFDA-NHS, (B) CFDA-COOH and (C) CFDA-
cisplatin-TRIS. 
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Therefore, several organic solvents (acetonitrile, methanol), an additive to the 
aqueous solvent (ammonium acetate) and different gradient methods were tested 
and evaluated regarding their separation performance. In the first tests the best 
results were gained using water and acetonitrile in a gradient method. Here, an 
influence of the pH of the solvents on the separation performance was tested by 
addition of ammonium acetate (CH3COONH3) at a concentration of 0.1 mM to the 
aqueous phase. Subsequently, the pH was adjusted in 0.5 unit steps in the range of 
4.5 to 8.0 by CH3COOH or NaOH (see Appendix A). However, the results showed no 
improvement of the separation capability over water without additives in the order of 
pH 7. In the pH range < 6 CFDA-cisplatin decomposed and the chromatographic 
results deteriorated, showing increasing peaks of byproducts (Appendix A). Hence, 
the addition of a pH modifier was omitted. After the optimization of the gradient 
method (see 3.2) using water and acetonitrile without any additives, CFDA-cisplatin 
purity could be raised to more than 95% and the compound was regarded suitable for 
cell culture experiments. The final gradient showed a baseline separation of CFDA-
cisplatin and its impurities, which was needed for the reliable collection of CFDA-
cisplatin (Figure 12). The fractions were analyzed by subsequent LC-MS analysis. 
The double peak at 28 to 30 min showed the mass of CFDA-cisplatin in both spikes. 
This may be explained by the mixture of two isomers of CFDA (5-carboxy-fluorescein 
diacetate and 6-carboxyfluorescein diacetate) that has been used in the synthesis. 
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Figure 12 Chromatogram of a semi-preparative HPLC purification run of CFDA-cisplatin. 
The double-peak at 28 to 30 min contains CFDA-cisplatin. 
The differences between the CFDA-cisplatin batches after synthesis and after 
purification as measured by CE-LIF by Robert Zabel at the ISAS Institute in 
Dortmund, are shown in Figure 13. As explained above, the crude product of CFDA-
cisplatin after synthesis still contained byproducts (Figure 13 a), which were identified 
using CE-MS as CFDA-TRIS (structure in Figure 11 B), which resulted of the reaction 
of CFDA-NHS ester with TRIS, and CFDA-COOH, which resulted of the reaction of 
CFDA-NHS with water. By increasing the amount of precursor in the last step of the 
synthesis procedure a product with favorable byproduct profile could be produced, 
but it still contained impurities (Figure 13b). After the HPLC purification procedure a 
peak of highly purified CFDA-cisplatin (in a complex with TRIS, Figure 11 C) with 
only negligible peaks of the impurities was detectable by CE-LIF and CE-MS (Figure 
13d) [155]. 
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Figure 13 Electropherograms after incubation in TBS overnight at 37 °C of (a) CFDA-
cisplatin prepared according to Molenaar et al. [109], (b) CFDA-cisplatin 
prepared using an excess of platinum precursor Boc-Pt as described in [155], 
(c) CFDA-NHS and (d) purified CFDA-cisplatin. Identified peaks: (1) CFDA-
cisplatin-TRIS, (2) CFDA-TRIS, (3) CFDA-COOH [155]. 
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4.2 Identification of proteins interacting with CFDA-cisplatin 
For the identification of proteins interacting with cisplatin by 2D gel electrophoresis 
the sample complexity was reduced by fractionation of the whole cell lysate into three 
fractions using differential centrifugation (see 3.4). The efficiency of the fractionation 
procedure was verified by Western Blot. The nuclear marker protein lamin B1, the 
mitochondrial marker protein COX IV and the cytosolic marker protein GAPDH were 
analyzed. After differential centrifugation of the lysate, the cytosolic fraction was 
almost completely cleared of nuclear and mitochondrial remnants and suitable for the 
subsequent experiments (Figure 14). There were only slightly visible bands for the 
respective marker proteins lamin B1 and COX IV detectable, whereas the nuclear 
and mitochondrial fraction showed strong bands. 
 
Figure 14 Representative Western Blot after fractionation of A2780 and A2780cis cells. 
Nuclear marker protein lamin B1, mitochondrial marker protein COX IV and 
cytosolic marker protein GAPDH were detected in the three fractions. 
After incubation of cells with 25 µM CFDA-cisplatin for 2 h, cells were fractionated as 
described in section 3.4. The following experiments were performed by Sandra Kotz 
from the University of Cologne with the cytosolic fractions that were prepared in 
Bonn. The cytosolic fraction was further analyzed by 2D gel electrophoresis. The 
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simultaneous introduction of an on-gel reference protein marker grid during 2D gel 
electrophoresis increased the validity of the subsequent analysis [111,156]. 
 
Figure 15 Visualisation of CFDA-cisplatin-protein adducts by 2D gel electrophoresis. 
A2780cis cells were treated with 25 µM CFDA-cisplatin for 2h (A). The 
generation of a reference protein spot grid (B) allowed the separation in parallel 
with 150 µg cytosolic proteins through 2DE. A fluorescence scan was recorded 
(CFDA-cisplatin: excitation/emission: 488 nm/532 nm (A); SERVA Lightning Red 
for 1D SDS-PAGE: excitation/emission: 532 nm/580 nm (B)) and the proteins 
were visualised with Coomassie staining (C). For the image analysis the 
fluorescence scans from CFDA-cisplatin-protein adducts (A) as well as from 
protein marker grid (B) and the Coomassie staining image (C) were fused to a 
master image (D) [111]. 
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As shown in Figure 15, after the 2D gel electrophoresis it was possible to assign 
fluorescent signals (colored in orange) to distinct protein spots (Coomassie stained in 
blue). Subsequently, these protein spots were excised from the gel. After enzymatic 
digestion, the proteins showing fluorescence were identified by ESI-MS analysis. In 
the pH range 4 to 7 the protein disulfide isomerases PDIA1 and PDIA3 as well as 
78 kDa glucose-regulated protein (GRP78) were identified among others (Table 7) 
[111]. The contribution of these proteins was assessed in the following screening 
approach. 
Table 7 Identified proteins after 2D gel electrophoresis and ESI-MS analysis of CFDA-
cisplatin treated A2780 and A2780cis cytosolic fractions. 
Protein name Gene name Accession number 
Protein disulfide isomerase A1 PDIA1 P07237 
Protein disulfide isomerase A3 PDIA3 P30101 
Protein disulfide isomerase A6 PDIA6 Q15084 
78 kDa glucose-regulated protein HSPA5 P11021 
ß-Actin ACTB P60709 
Vimentin VIM P08670 
4.3 Optimization of siRNA experiments 
The transient siRNA-mediated knockdown of a target protein plays a central role in 
the following experiments evaluating the contribution of the respective protein to 
cisplatin resistance. With the aid of a fluorescent siRNA (siGLO® siRNA) the 
conditions for an optimal transfection were assessed. Experience from previous 
studies in the workgroup showed that the selection of a potent transfection reagent 
was crucial for transfection efficiency, therefore two different reagents were tested 
(K2® transfection system, Biontex Laboratories GmbH; jetprime®, Polyplus 
Transfection). As confirmed by fluorometric analysis after transfection, the K2® 
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reagent showed the more efficient transfection of siGLO® siRNA in the cell lines used 
(A2780, A2780cis) (Figure 16) with at least a doubling in fluorescence compared to 
control cells transfected without siRNA. Therefore, it was chosen for further 
experiments. 
 
Figure 16 siGLO® transfection efficiency in A2780 (A) and A2780cis (B) cells. Different 
concentrations of transfection reagent were used with 50 nM of siGLO siRNA for 
20.000 or 30.000 cells/well. Fluorescence was compared to control cells 
transfected without siRNA (mean ± SD, N = 3). 
The final concentration of K2® reagent for an efficient transfection was determined in 
a similar fashion as before (Figure 17). At the same time the impact of the 
transfection on cell viability was assessed by the MTT assay (Figure 18). All results 
were recorded for three different cell densities between 10000 and 30000 cells per 
well. Combining both factors, the optimal conditions for transfection were determined 
(highest transfection efficiency with lowest impact on viability of cells). 
In A2780 cells, the efficiency of transfection for 10000 cells per well was best with 
0.75 µL K2® per well, whereas for 20000 and 30000 cells per well it was best for 
0.5 µL K2® per well. For A2780cis cells, 0.5 µL K2® per well resulted in the highest 
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transfection efficiency for a number of 10000 and 20000 cells per well. The most 
favorable transfection profile for 30000 cells per well was observed with a higher 
volume of 0.75 µL K2® per well. 
 
Figure 17 Fluorescence of siGLO® siRNA after transfection in (A) A2780 and (B) A2780cis 
cells using different volumes of K2® transfection reagent and 50 nM of siGLO® 
siRNA (mean ± SD, N = 3). 
 
Figure 18 Viability of (A) A2780 and (B) A2780cis cells after transfection of siGLO® siRNA 
using different volumes of K2® transfection reagent and 50 nM of siGLO® siRNA 
(mean ± SD, N = 3). 
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The transfection reagent had a dose-dependent influence on cell viability, with the 
transfection with the highest volume of 1 µL per well being the most cytotoxic. The 
resistant cell line A2780cis was more robust against the toxic effect of the 
transfection reagent than A2780 cells. 
Based on these results, a volume of 0.5 µL K2® transfection reagent per well was 
chosen for all further experiments as it showed good to very good transfection results 
(Figure 17) with an acceptable influence on cell viability in both cell lines (Figure 18). 
The volume was scaled to a 6-well plate for further experiments according to the 
recommendations of the manufacturer. 
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4.4 GRP78  
4.4.1 siRNA knockdown 
The contribution of GRP78 to cisplatin detoxification in the cytoplasm and to 
apoptosis induction after cisplatin treatment was analyzed after a transient siRNA-
mediated silencing of GRP78 in A2780 and A2780cis cells. Using Western Blot 
analysis, the expression of GRP78 in cells without knockdown was compared to 
negative knockdown and GRP78 knockdown cells. All results are related to the 
expression of GAPDH as a housekeeper protein.  
 
Figure 19 Representative Western Blot and corresponding densitometric quantification of 
the expression (bar graph) of GRP78 in A2780 and A2780cis cells either without 
knockdown (untreated) or treated with the respective siRNA (negative control or 
GRP78). Results of untransfected cells were set to 100%. GAPDH was used as 
housekeeping protein (mean ± SD, N = 3). 
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The knockdown with a negative siRNA (non-coding base sequence, see 3.7) showed 
a small influence on GRP78 expression in A2780cis cells, reducing the expression to 
70 ± 10%. In A2780 cells the negative knockdown led to comparable levels of 
GRP78 in comparison to cells without knockdown (91 ± 10%). If transfected with 
GRP78-specific siRNA [40 nM], the expression of GRP78 was reduced to 59 ± 9% 
and 37 ± 8% in A2780 and A2780cis cells, respectively (Figure 19). The 
concentration of 40 nM was considered suitable, as lower concentrations (< 40 nM) 
exhibited a decrease in knockdown efficiency, whereas higher concentrations 
(> 40 nM) produced a decrease in cell viability, particularly in A2780 cells. All results 
are detailed in Appendix B1. 
4.4.2 Cisplatin cytotoxicity 
Cisplatin cytotoxicity after GRP78 knockdown was assessed using the MTT assay. 
 
Figure 20 Cisplatin cytotoxicity in A2780 and A2780cis cells assessed without knockdown, 
and GRP78 knockdown (mean ± SEM, N = 6 - 9). 
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Results for A2780 cells show a slight tendency for decreased pEC50 values between 
cells without knockdown (5.38 ± 0.04, mean ± SEM) and with GRP78 knockdown 
(5.32 ± 0.06, mean ± SEM) with no significant difference (p = 0.379) (Figure 20). 
A2780cis cells exhibited also a non-significant (p = 0.337) decrease of the pEC50 
value from 4.78 ± 0.04 to 4.70 ± 0.04 (mean ± SEM) after knockdown, rather 
suggesting an increase in resistance after knockdown. All results are detailed in 
Appendix B2. 
4.4.3 Apoptosis induction 
The induction of apoptosis is regarded as one of the final steps in the mechanism of 
action of cisplatin. The transfection itself had an impact on the cell viability. Hence, in 
order to compensate for the apoptosis-inducing effect of the knockdown procedure, 
the ratio of the percentage of apoptotic cells after knockdown and subsequent 
cisplatin incubation to the percentage of apoptotic cells in corresponding control 
experiments without cisplatin was calculated. As internal control, simultaneously cells 
without knockdown were tested using the same procedure. In order to investigate the 
cisplatin effect on both stages of apoptosis, the early apoptotic (EA) and late 
apoptotic (LA) cell population was analyzed separately. 
Cisplatin exposure strongly induced early and late apoptosis in A2780 cells (fold 
change: EA 2.6 ± 1.0, LA: 4.3 ± 0.7, mean ± SD). As expected in resistant cells, 
cisplatin induced apoptosis to a lesser extent, for EA the fold change was 1.3 ± 0.4 
and for LA 1.4 ± 0.4. As mentioned above, the knockdown procedure alone was 
cytotoxic and induced apoptosis, possibly caused by its influence on cellular 
functions. Thus, results for negative knockdown and GRP78 knockdown have to be 
interpreted accordingly. In A2780 cells the knockdown procedure influenced the 
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induction of apoptosis even stronger than in A2780cis cells. Compared to cells 
without knockdown an increase of early apoptotic A2780 cells after the negative 
knockdown was noted. After GRP78 knockdown, A2780 cells present a far lower fold 
change of apoptotic cells (EA: 1.4 ± 0.5, LA: 1.3 ± 0.3, mean ± SD) than after 
negative knockdown cells (EA: 3.3 ± 2.5, LA: 1.9 ± 0.3, mean ± SD) (Figure 21). In 
resistant cells, early apoptosis after GRP78 knockdown was induced to a slightly 
greater extent (EA: 1.9 ± 0.5, mean ± SD), compared to cells with negative 
knockdown (EA: 1.3 ± 0.8, mean ± SD) and without knockdown (EA: 1.3 ± 0.4, 
mean ± SD). However, late apoptosis remained on the same level after GRP78 
knockdown (LA: 1.5 ± 0.4, mean ± SD) as after negative knockdown (LA: 1.5 ± 1.1, 
mean ± SD) or without knockdown (LA: 1.4 ± 0.4, mean ± SD). All results are detailed 
in Appendix B3. 
 
Figure 21 Cisplatin-associated apoptosis induction in A2780 and A2780cis cells assessed 
without knockdown, after negative or GRP78 knockdown. Fold change of the 
percentage of (A) early apoptotic (EA) and (B) late apoptotic (LA) cells after a 24 
h incubation with 10 µM cisplatin related to a corresponding control experiment 
without cisplatin treatment (mean ± SD, N = 3 - 6).  
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4.5 PDIA1 
4.5.1 siRNA knockdown 
In A2780 and A2780cis cells a negative knockdown showed no influence on PDIA1 
expression with PDIA1 levels comparable to cells without knockdown (Figure 22). 
After transfection of PDIA1-specific siRNA the expression was reduced to 
44.9 ± 3.4% and 47.4 ± 4.1 % of its basal level in A2780 and A2780cis cells, 
respectively (Figure 22). All results are detailed in Appendix C1. 
 
Figure 22 Representative Western Blot and corresponding densitometric quantification of 
the expression (bar graph) of PDIA1 in A2780 and A2780cis cells either without 
knockdown (untreated) or treated with the respective siRNA (negative control or 
PDIA1). Results of untreated cells were set to 100%. GAPDH was used as 
housekeeping protein (mean ± SD, N = 3). 
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4.5.2 Cisplatin cytotoxicity 
After PDIA1 knockdown, the MTT assay revealed a slight and not significant 
sensitization to cisplatin treatment (p = 0.06) for A2780 cells. However, cisplatin-
resistant A2780cis cells were significantly sensitized to cisplatin after PDIA1 
knockdown compared to either negative knockdown controls (p = 0.019) or controls 
without knockdown (p = 0.046) (Figure 23). All results are detailed in Appendix C2. 
 
Figure 23 Cisplatin cytotoxicity in A2780 and A2780cis cells without knockdown, negative 
knockdown and PDIA1 knockdown (mean ± SEM, N = 3 - 6). 
4.5.3 Apoptosis induction 
As expected, cisplatin exposure generally induced early and late apoptosis in A2780 
cells (fold change: EA: 3.5 ± 0.8; LA: 3.9 ± 1.3, mean ± SD) and to a lower extent in 
A2780cis cells (EA: 2.1 ± 1.2; LA: 2.4 ± 0.6, mean ± SD). Within the same cell line no 
significant differences in early and late apoptosis induced by cisplatin were found 
between the different knockdown experiments. However, some trends were 
observed. In sensitive A2780 cells, apoptosis induction by cisplatin was not affected 
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by PDIA1 knockdown exhibiting EA and LA ratios comparable to negative knockdown 
cells (Figure 24). In resistant A2780cis cells, PDIA1 knockdown led to higher ratios of 
EA and LA cells (EA: 3.5 ± 2.1; LA: 2.2 ± 1.0, mean ± SD) compared to negative 
knockdown cells (EA: 1.4 ± 0.9; LA: 1.4 ± 0.9, mean ± SD), indicating a cisplatin-
sensitizing effect of PDIA1 knockdown in these cells. All results are detailed in 
Appendix C3. 
 
Figure 24 Cisplatin-associated apoptosis induction in A2780 and A2780cis cells assessed 
without knockdown, after negative or PDIA1 knockdown. Fold change of the 
percentage of (A) early apoptotic (EA) and (B) late apoptotic (LA) cells after a 24 
h incubation with 10 µM cisplatin related to a corresponding control experiment 
without cisplatin treatment (mean ± SD, N = 3 - 6). 
4.5.4 DNA platination 
The platination of nuclear DNA is regarded as the main cornerstone of the cytotoxic 
mechanism of action of cisplatin [157]. Thus, the DNA platination after knockdown of 
PDIA1 was investigated under two different conditions (high cisplatin concentration, 
short incubation time (HS) [100 µM cisplatin, 4 h] and low cisplatin concentration, 
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long incubation time (LL) [5 µM cisplatin, 24 h]). Control experiments were performed 
using cells without knockdown and negative knockdown cells. HS incubation of 
A2780 cells after PDIA1 knockdown showed no difference in the DNA platination 
compared to the control cells without knockdown and negative knockdown cells 
(without knockdown: 220.3 ± 16.0 pg Pt/µg DNA; neg. knockdown: 205.9 ± 29.8 
pg Pt/µg DNA; PDIA1 knockdown: 198.4 ± 19.8 pg Pt/µg DNA, mean ± SD) (Figure 
25). In contrast, LL incubation led to slightly higher DNA platination after PDIA1 
knockdown, especially compared to cells without knockdown (without knockdown: 
17.5 ± 4.4 pg Pt/µg DNA; neg. knockdown: 20.2 ± 3.2 pg Pt/µg DNA; PDIA1 
knockdown: 21.9 ± 2.3 pg Pt/µg DNA, mean ± SD) (Figure 26). The resistant cells 
showed a different pattern. Here, HS incubation after PDIA1 knockdown led to an 
increased DNA platination (without knockdown: 75.7 ± 33.4 pg Pt/µg DNA; neg. 
knockdown: 113.4 ± 20.8 pg Pt/µg DNA; PDIA1 knockdown: 127.4 ± 38.9 
pg Pt/µg DNA, mean ± SD) (Figure 25). 
 
Figure 25 DNA platination after incubation with 100 µM cisplatin for 4 h in A2780 and 
A2780cis cells assessed without knockdown, after negative or PDIA1 
knockdown (mean ± SD, N = 3). 
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The LL incubation showed mixed results, as the negative knockdown had the highest 
influence on DNA platination and PDIA1 knockdown led to platinum levels 
comparable to cells without knockdown (without knockdown: 
12.8 ± 7.1 pg Pt/µg DNA; neg. knockdown: 22.8 ± 4.5 pg Pt/µg DNA; PDIA1 
knockdown: 14.5 ± 5.7 pg Pt/µg DNA, mean ± SD) (Figure 26). After LL incubation 
the ratio of DNA platination between sensitive and resistant cells without knockdown, 
with negative knockdown and with PDIA1 knockdown was reduced to a factor of 
1.37, 0.89 and 1.33, respectively. After HS incubation this ratio was 3.71, 1.82 and 
1.56, respectively. All results are detailed in Appendix C4 
 
Figure 26 DNA platination after incubation with 5 µM cisplatin for 24 h in A2780 and 
A2780cis cells assessed without knockdown, after negative or PDIA1 
knockdown (mean ± SD, N = 3). 
4.5.5 Pharmacological inhibition of PDIA1 by PACMA31 
To better understand the role of PDIA1 for acquired cisplatin resistance the effect of 
the recently described irreversible PDI inhibitor PACMA31 on cisplatin cytotoxicity 
was investigated [140]. PACMA31 has been reported to be selective for PDIA1 over 
other protein families, but its selectivity over other PDI isoforms is not yet known. 
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First, the cytotoxic effect of PACMA31 on A2780 and A2780cis cells alone and then 
in combination with cisplatin was analyzed.  
Table 8 Cytotoxicity of PACMA31 in A2780 and A2780cis cells (mean ± SEM, N = 9). 
 A2780 A2780cis 
pEC50 6.47 ± 0.05 6.40 ± 0.06 
EC50 [µM] 0.37 0.46 
pEC10 6.62 ± 0.07 6.50 ± 0.05 
EC10 [µM] 0.29 0.35 
 
The EC50 and EC10 of PACMA31 were determined (Table 8). The results show that 
PACMA31 is highly cytotoxic in A2780 and A2780cis cells with markedly lower EC50 
values than cisplatin. The resistance factor for PACMA31 was 1.2. 
 
Figure 27 Cisplatin cytotoxicity in A2780 and A2780cis cells without and with co-incubation 
with 0.2 µM PACMA31 (mean ± SEM, N = 3 - 6). 
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In a second experiment, the cytotoxicity of a combination of PACMA31 at a 
concentration of 0.2 µM (which is lower than its EC10 concentration) together with 
cisplatin was investigated. Whereas sensitivity of A2780 cells did not significantly 
change, A2780cis cells were significantly sensitized to cisplatin treatment (p = 0.015) 
(Figure 27). The resistance factor decreased from 4.3 ± 0.06 to 2.5 ± 0.27 
(mean ± SEM, N = 3-6, p = 0.0032) upon addition of PACMA31 at the concentration 
of 0.2 µM. All results are detailed in Appendix D1. 
In a further step it was investigated if a pharmacological inhibition of PDIA1 had any 
influence on DNA platination. Similar conditions as in the previous experiments were 
applied, such as HS with 100 µM cisplatin for 4 h and LL with 5 µM cisplatin for 24 h. 
Co-incubation with 0.2 µM or 0.4 µM PACMA31 at the HS conditions caused a 
slightly and not significantly reduced DNA platination in A2780 and A2780cis cells 
(Figure 28).  
 
Figure 28 DNA platination after incubation with 100 µM cisplatin for 4 h in A2780 and 
A2780cis cells and co-incubation with 0.2 µM or 0.4 µM PACMA31 (mean ± SD, 
N = 3 - 6). 
At the LL conditions, a tendency for reduced DNA platination upon 0.2 µM PACMA31 
co-incubation was observed whereas the tendency was smaller in the case of 0.4 µM 
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PACMA31. In A2780cis cells, a co-incubation with 0.2 µM PACMA31 showed no 
influence and 0.4 µM PACMA31 led to a slight increase of platinated DNA (Figure 
29). 
 
Figure 29 DNA platination after incubation with 5 µM cisplatin for 24 h in A2780 and 
A2780cis cells and co-incubated with 0.2 µM or 0.4 µM PACMA31 (mean ± SD, 
N = 3 - 6). 
In order to further assess the potential of PACMA31 to overcome cisplatin resistance, 
the combination index according to Chou was determined [152]. Combination of 
increasing concentrations of cisplatin and PACMA31 were tested in an MTT assay. 
For the combination of PACMA31 with cisplatin in sensitive A2780 cells a synergistic 
effect at effective concentration combinations higher than EC90 with the strongest 
synergism at EC95 was found. At the EC50 and EC75 concentration both drugs act as 
antagonists in A2780 cells, reducing the expected cytotoxic effect. In resistant 
A2780cis cells the synergistic effect was much more pronounced. Here, a CI value 
lower than 1 was already determined at the EC75 concentration (Figure 30). Again, 
the strongest effect was found at EC95 concentration. At the EC50 concentration both 
drugs showed an additive effect in A2780cis cells (CI = 1). All results are detailed in 
Appendix D3. 
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Figure 30 Combination index (CI) for PACMA31 and cisplatin in A2780 and A2780cis 
cells. CI was determined for EC50 to EC95 (mean ± SD, N = 9). 
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4.6 PDIA3 
4.6.1 siRNA knockdown 
After PDIA3 knockdown, the expression of PDIA3 in A2780 and A2780cis cells was 
reduced to 40.4 ± 9.9% and to 16.5 ± 9.8% of its basal level in untreated cells, 
respectively (Figure 31). The negative knockdown did not affect PDIA3 expression in 
A2780 (107.2 ± 6.5%) and A2780cis cells (91.5 ± 16.7%). All results are detailed in 
Appendix E1. 
 
Figure 31 Representative Western Blot and corresponding densitometric quantification of 
the expression (bar graph) of PDIA3 in A2780 and A2780cis cells either without 
knockdown (untreated) or treated with the respective siRNA (negative control or 
PDIA3). Results of untreated cells were set to 100%. GAPDH was used as 
housekeeping protein (mean ± SD, N = 3). 
4.6.2 Cisplatin cytotoxicity 
In A2780 cells a knockdown of PDIA3 had no influence on cisplatin cytotoxicity. The 
pEC50 values are comparable for the three conditions investigated (without 
knockdown: 5.37 ± 0.03; negative knockdown: 5.36 ± 0.04; PDIA3 knockdown: 
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5.39 ± 0.03. mean ± SEM) (Figure 32). In A2780cis cells, a slight but not significant 
desensitizing tendency of PDIA3 knockdown was observed (without knockdown: 
4.88 ± 0.03; negative knockdown: 4.85 ± 0.03; PDIA3 knockdown: 4.80 ± 0.02, 
mean ± SEM). All results are detailed in Appendix E2. 
 
Figure 32 Cisplatin cytotoxicity in A2780 and A2780cis cells assessed without knockdown, 
negative knockdown and PDIA3 knockdown (mean ± SEM, N = 5 - 7). 
4.6.3 Apoptosis induction 
After PDIA3 knockdown in A2780 cells, cisplatin treatment showed a decreased 
apoptosis-inducing effect (EA: 1.4 ± 0.3; LA: 1.3 ± 0.1, mean ± SD) (Figure 33). This 
may be explained by a stronger apoptosis-inducing effect of the PDIA3 knockdown 
alone. Still, some apoptosis-inducing effect of cisplatin was detectable as the ratio 
after PDIA3 knockdown with cisplatin and without cisplatin was greater than 1. In 
A2780cis cells PDIA3 knockdown showed comparable ratios as negative knockdown 
for EA (1.2 ± 0.3 vs. 1.4 ± 0.9, mean ± SD) and LA (1.2 ± 0.3 vs. 1.4 ± 0.9, 
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mean ± SD) indicating no cisplatin-sensitizing effect of PDIA3 knockdown. All results 
are detailed in Appendix E3. 
 
Figure 33 Cisplatin-associated apoptosis induction in A2780 and A2780cis cells assessed 
without knockdown, after negative or PDIA3 knockdown. Fold change of the 
percentage of (A) early apoptotic (EA) and (B) late apoptotic (LA) cells after a 
24 h incubation with 10 µM cisplatin related to a corresponding control 
experiment without cisplatin treatment (mean ± SD, N = 3 - 6). 
4.6.4 DNA platination 
Interestingly, HS incubation of A2780 cells after PDIA3 knockdown significantly 
increased the DNA platination compared to cells with a negative knockdown 
(without knockdown: 318.9 ± 44.2 pg Pt/µg DNA; neg. knockdown: 324.1 ± 20.8 
pg Pt/µg DNA, PDIA3 knockdown: 383.6 ± 30.4 pg Pt/µg DNA, mean ± SD) (Figure 
34). A comparable but not significant increase in A2780 cells was detectable after LL 
incubation (without knockdown: 21.1 ± 7.5 pg Pt/µg DNA; negative knockdown: 
59.9 ± 15.6 pg Pt/µg DNA; PDIA3 knockdown: 68.7 ± 35.6 pg Pt/µg DNA, 
mean ± SD) (Figure 35). Again, the resistant cells showed a different pattern. HS 
incubation after PDIA3 knockdown led to a similar DNA platination compared to 
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negative knockdown (without knockdown: 102.3 ± 32.3 pg Pt/µg DNA; negative 
knockdown: 155.0 ± 56.8 pg Pt/µg DNA, PDIA3 knockdown: 136.1 ± 68.7 
pg Pt/µg DNA, mean ± SD). 
 
Figure 34 DNA platination after incubation with 100 µM cisplatin for 4 h in A2780 and 
A2780cis cells assessed without knockdown, after negative or PDIA3 
knockdown (mean ± SD, N = 5). 
After LL incubation the negative knockdown showed lower DNA platination than the 
PDIA3 knockdown in A2780cis cells (without knockdown: 15.3 ± 3.2 pg Pt/µg DNA; 
negative knockdown: 39.3 ± 36.5 pg Pt/µg DNA; PDIA3 knockdown: 49.9 ± 32.9 
pg Pt/µg DNA, mean ± SD). The ratio of DNA platination between sensitive and 
resistant cells without knockdown, with negative knockdown and with PDIA3 
knockdown was 3.12, 2.09 and 2.82 after HS incubation, respectively. After LL 
incubation the ratio was reduced to factors of 1.38, 2.56 and 1.80, respectively. All 
results are detailed in Appendix E4. 
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Figure 35 DNA platination after incubation with 5 µM cisplatin for 24 h in A2780 and 
A2780cis cells assessed without knockdown, after negative or PDIA3 
knockdown (mean ± SD, N = 5). 
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5 DISCUSSION 
5.1 Purification of CFDA-cisplatin 
CFDA-cisplatin (CFDA-Pt) was introduced in 2000 by Molenaar et al. as a model 
substance, enabling researchers to follow the distribution and the intracellular protein 
binding of cisplatin [109]. After the synthesis of CFDA-cisplatin according to the 
literature procedure, first results of the LC-MS characterization of the final product 
revealed several major impurities, while the yield of CFDA-cisplatin was only about 
40% [109,155]. The original synthesis by Molenaar et al. reported yields of 55-70%, 
which however was impossible to reproduce [109]. The capillary electrophoresis with 
laser-induced fluorescence detection (CE-LIF) analysis of the product, with a limit of 
detection in the low attomolar (picogram) concentration range, detected fluorescent 
impurities, which were proved to carry a CFDA moiety [155]. By an on-line CE-MS 
coupling the identification of the main impurities was possible. It became clear that 
the CFDA-NHS ester, which was one of the educts used in the synthesis, was still 
present. Furthermore, CFDA-COOH was identified which is formed upon the reaction 
of CFDA-NHS with water [155]. The impurities could potentially lead to false-positive 
results by producing signals after binding of CFDA-NHS to proteins. Hence, the 
purification of the final product was necessary. The most practicable approach was 
the semi-preparative high performance liquid chromatography (HPLC). Several 
columns were tested, such as the reversed-phase Nucleodur C18 Gravity® and 
Nucleodur HTec C18®. The latter revealed a suitable performance for the purification 
of CFDA-cisplatin. Several methods were tested during the optimization process of 
the method, such as an isocratic elution with H2O/acetonitrile 30%/70%. The finally 
established method used a gradient of H2O/acetonitrile from 80%/20% to 5%/95% 
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enabling base-line separation of CFDA-cisplatin and its impurities. The purified 
product was analyzed by LC-MS and again by CE-LIF. After all, CFDA-cisplatin 
showed a purity of at least 95% [155]. This was sufficient for the subsequent in vitro 
and other experiments. The crucial purification step greatly improved the reliability as 
well as the confidence in the screening approach and the following experiments. 
A drawback for the purification process was the time-consuming HPLC run, which 
lasted 44 minutes. As described above, this was necessary to achieve base-line 
separation. Furthermore, the loss of product upon purification was around 50%, 
which was higher than expected. This suggests that during the purification some of 
the substance either decayed or got lost due to the HPLC setup. 
5.2 siRNA transfection 
Since the discovery and spreading application in life sciences, the methods for siRNA 
transfection have been steadily improved. Still, the interplay between the most 
effective siRNA for a target protein in a cell and the transfection reagent has great 
impact on knockdown efficiency [158]. Thus, the experimental conditions always 
need to be optimized for each cell line transfected for the first time [159]. 
The time and costs to design and evaluate an effective siRNA were saved by using 
siRNA validated by the manufacturer (Qiagen) [160]. As stated in 4.3, the K2® 
transfection reagent was compared with other commercially available products. 
Results for the A2780 cell line were most encouraging in the case of the K2® 
transfection reagent, which was therefore used in this study. 
Various methods to assess transfection efficiency exist. For example, the transfection 
with a cell death control siRNA leads the cell into apoptosis and transfection 
efficiency can be simply correlated to cell viability. As a simultaneous measurement 
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of the transfection efficiency and apoptosis initiation was needed, the transfection of 
a fluorescent siRNA followed by a MTT assay was regarded as a feasible alternative 
[161]. Here, the measurement of fluorescence intensity after transfection can be 
correlated with transfection efficiency [162]. Subsequently, the absorption of 
formazan after MTT treatment correlates with the cell viability after the transfection 
procedure. In order to increase the comparability between experiments, the 
experimental conditions determined by this approach were then used in all following 
experiments. 
The therapeutic application of siRNA to treat diseases in humans is developing with a 
pace seen never before in the development of an entirely new therapeutic approach. 
From the first discovery of specific post-translational gene silencing in C. elegans in 
1998 by Mello and Fire, researchers brought siRNA therapy to the clinics as early as 
2010 [163,164]. The potential of siRNA therapy is enormous having the ability to 
ameliorate basically every human disease that is caused by over-expression of a 
specific protein [165]. However, remaining obstacles need to be elucidated and are 
currently being tackled to improve siRNA therapy. The main problem is the safe and 
efficient delivery of siRNA to the target tissue [166]. Several approaches have 
already proven their efficacy to deliver siRNA in vivo, such as polymers or lipids 
[166]. Targeting the siRNA to cancer cell-specific receptors can improve its 
distribution. For example, around 95% of ovarian epithelial carcinomas express the 
scavenger receptor B1 (SR-B1). Therefore, delivery of siRNA targeted to SR-B1 
showed an even distribution of ~80% in a given tumor [167]. A further application for 
siRNA-based therapeutics is drug resistance in cancer which, as stated earlier, may 
be caused by over-expression of transporters or signaling pathway proteins [168]. 
Here, a combined treatment with siRNA and a chemotherapeutic drug may support 
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the management of drug resistance [169]. In a recent publication, the administration 
of siRNA and a cisplatin prodrug through nanoparticle-mediated codelivery showed 
promising results sensitizing cancer cells to therapy and proved to be efficacious in 
an animal model [170]. 
5.3 Contribution of GRP78 to acquired cisplatin resistance 
GRP78 is part of the heat shock protein family (HSP) and a master regulator of the 
unfolded protein response (UPR). As described in section 1.4.1, cells activate the 
UPR in order to cope with ER stress, which may occur after exposition to a 
chemotherapeutic agent [121]. Furthermore, the basal expression of GRP78 has 
been shown to be increased in several, mostly rapidly proliferating cancer entities 
such as melanoma, endometrial, breast, or prostate cancer [171–174]. It appears 
mandatory for these cancer cells to maintain their protein folding capacity even under 
stressed conditions for the rapid synthesis of new proteins. Interference with the 
mechanisms associated with an increased stress tolerance seems to be a 
reasonable approach to sensitize cells to cytotoxic treatment [175]. This has been 
shown in cell models of different cancer entities [176]. In melanoma cells (Mel-RM, 
MM200) cisplatin sensitivity was significantly increased after siRNA inhibition of 
GRP78 [171]. TuBEC cells, which were derived from blood vessels of malignant 
glioma tissues, showed highly elevated GRP78 expression and were resistant to 
etoposide and temozolomide treatment [177]. With a lentiviral construct expressing 
siRNA against GRP78 TuBEC cells were sensitized to the anticancer drugs [177]. 
Colorectal cancer cells have been sensitized to paclitaxel by inhibition of GRP78, 
leading to an increased activation of apoptosis-mediating proteins [178]. Two 
endometrial cancer cell lines (Ishikawa, AN3CA) could be sensitized to cisplatin 
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treatment by knockdown of GRP78 [172]. Additionally, Cali et al. showed that cell 
growth and invasiveness of these cell lines was reduced after silencing GRP78 [179]. 
Another approach includes administration of small molecules that inhibit the GRP78 
function. Epigallocatechin gallate (EGCG) is a major component of green tea and has 
been shown to exert many beneficial effects such as chemopreventive or 
anticarcinogenic effects. In TuBEC cells, combination of EGCG with temozolomoide 
or etoposide caused significantly more cell death than the drugs alone [177]. In 
breast cancer cells, etoposide resistance could be overcome by treatment with 
EGCG [180]. Genistein, an isoflavone and phytoestrogen which can be found e.g. in 
soybeans, has been shown to inhibit the growth of breast cancer cells by blocking the 
binding of a transcription factor to the GRP78 promoter thus inhibiting translation 
[181]. Recent results for the plant compound honokiol, a lignan which can be 
extracted e.g. from the southern magnolia, suggest a mechanism of action 
comparable to EGCG (binding the unfolded ATPase domain of GRP78), but a higher 
affinity for GRP78 than EGCG. This may explain the higher sensitivity of different 
cancer cell lines to honokiol [182]. These studies suggest a relevance of GRP78 for 
cancer progression and development of chemoresistance.  
Other authors report opposing results. Ahmad et al. transiently up-regulated GRP78 
in lung cancer cells, which led to a hypersensitization of cells to cisplatin [183]. Colon 
cancer cells pre-treated with 6-aminonicotinamide or 2-deoxyglucose over-expressed 
GRP78. The elevated GRP78 levels led to an increase in sensitivity to cisplatin, 1,3-
bis(2-chlorethyl)-1-nitrosourea (BCNU or carmustin) and melphalan [184]. This may 
be caused by the ability of GRP78 to induce apoptosis by activating PERK. The more 
GRP78 is available the more PERK is activated, enhancing the apoptosis inducing 
effect of cisplatin. 
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In order to elucidate the contribution of GRP78 to acquired cisplatin resistance in the 
ovarian cancer cells A2780 and A2780cis a knockdown was conducted. Investigation 
of cisplatin cytotoxicity using the MTT assay showed no significant changes. 
Interestingly, the resistance factor of A2780cis cells increased slightly after a GRP78 
knockdown. The results suggest a compensation mechanism in A2780cis cells. 
GRP78 acts as the master regulator of the UPR and supports the cellular survival 
after mild ER stress. The resistant cells may be able to deal with the ER stress 
independently of GRP78 activity, potentially through an upregulation of other ER 
stress signaling proteins such as ATF6 or IRE1. The results of the apoptosis assay 
present a slightly different picture than the MTT data. Here, apoptosis induction in 
sensitive cells was reduced after GRP78 knockdown, which may be due to an 
increased activation of the pro-survival pathways and a decreased activation of the 
pro-apoptotic pathways. A2780cis cells show a small increase in early apoptotic 
cells, but no change in late apoptotic cells. Here, it seems possible that the early pro-
apoptotic pathway is increasingly activated after GRP78 knockdown, at least in 
comparison to A2780cis cells with a negative knockdown. The results of the late 
apoptosis are in accordance with the MTT assay, as no difference between the 
investigated conditions could be detected. Interpretation of the results is limited by 
the influence of the knockdown. The knockdown of GRP78 reduced the protein 
expression only to around 60% of the basal level in A2780 and to 40% in A2780cis 
cells. It is possible that in A2780 cells the remaining GRP78 protein was able to fulfill 
its cellular tasks, supporting the reduction of ER stress levels. After the knockdown of 
a protein the proliferation of A2780cis cells changed to a lesser extent than that of 
A2780 cells, which may explain the higher knockdown efficiency in A2780cis cells. 
As this project concentrated on the functional protein, there was no evaluation of the 
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efficacy of the siRNA to inhibit mRNA transcription by quantitative real-time 
polymerase chain reaction. This additional transcriptome analysis should be 
considered in future projects, in order to increase the understanding of the cellular 
effects of the knockdown itself. Furthermore, it should be noted that the results are 
limited to a cisplatin exposure of 24 h. Induction of early apoptosis may be stronger 
at earlier time points whereas late apoptosis may need even longer exposure times.  
In addition, GRP78 expression may be salvaged by cisplatin incubation, which may 
restore GRP78 levels after cisplatin exposure to basal levels. The circumvention of 
this problem appears difficult. It may be possible to perform the knockdown 
simultaneously with cisplatin exposure, but the results would need special 
interpretation, as the knockdown itself always exhibits a mild cytotoxic effect. 
Furthermore, various possible reactions of siRNA with cisplatin have been reported. 
In one study, the platination of the sense-strands in siRNA did not abolish the gene 
silencing activity in vitro [185]. However, the same group showed later that cisplatin 
did interfere with the siRNA silencing capacity [186]. A permanent knockdown using 
a shRNA construct may also be considered but may lead to other problems in return 
such as the comparability of shRNA-transfected cells to wild-type cells. For shRNA-
knockdown a compensatory protein upregulation has been described in vitro and in 
vivo [187,188]. In summary, the results suggest that in A2780 and A2780cis cells the 
siRNA-mediated knockdown of GRP78 has no significant effect on cisplatin 
cytotoxicity after 48 h or on cisplatin-induced apoptosis after 24 h. 
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5.4 Contribution of PDIA1 to acquired cisplatin resistance 
5.4.1 Effects of siRNA knockdown 
Protein disulfide isomerases exhibit intracellular functions, which mainly support 
cellular homeostasis. Depending on the substrate, they form (oxidize), break (reduce) 
or rearrange (isomerize) disulfide bonds in proteins [126]. Since PDIA1 is able to 
fulfill various intracellular tasks, the role of PDIA1 comprehensibly appears cell-type 
specific. In HeLa cells, a PDIA1 knockdown showed no significant effect on viability, 
whereas in MCF-7 cells the same knockdown was cytotoxic [189]. It has recently 
been shown that an upregulation of PDIA1 in glioblastoma is associated with 
resistance against temozolomide (TMZ). Again, the effect of a PDIA1 knockdown on 
TMZ cytotoxicity was cell-line dependent with the strongest effects of knockdown in 
TMZ-resistant D54-R cells [190]. The study described here suggests a similar pattern 
in ovarian cancer cells, as the cisplatin-resistant A2780cis cells are significantly 
sensitized to cisplatin treatment after PDIA1 knockdown, whereas in sensitive A2780 
cells only a tendency for a sensitization to cisplatin treatment after PDIA1 knockdown 
was observed. Additionally, a tendency to increased apoptosis in the early and late 
stage upon cisplatin treatment in A2780cis cells after PDIA1 knockdown was 
observed, which is in agreement with the results of the MTT assay. There was no 
significant change in the amount of platinated DNA detectable after the PDIA1 
knockdown. This implies that the increased cytotoxicity and apoptosis induction may 
be independent of cisplatin binding to the nuclear DNA. Cisplatin potentially exerts its 
effect additionally by an extra-nuclear mechanism. An increase in ER stress levels 
after the PDIA1 knockdown seems possible, which has been associated with 
cisplatin cytotoxicity in cytoplasts (enucleated cells) [191]. If the chaperone activity of 
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PDIA1 is lost the cell is not able to reduce the increasing amount of misfolded 
proteins. Compensation mechanisms by other chaperones may not be sufficient to 
limit the ER stress to an acceptable level. 
It is important to consider that the apoptosis results reported, are limited to a cisplatin 
exposure of 24 h and 10 µM cisplatin. Therefore, it may be interesting to investigate 
the time- and concentration-dependence of the cisplatin-sensitizing effect of the 
PDIA1 knockdown. The results of the DNA platination experiments may be limited 
due to the complex experimental setting which introduces more variability than the 
MTT or apoptosis assay. The multiple steps include (I) the knockdown procedure, (II) 
cisplatin exposure and (III) DNA extraction. This is followed by (IV) DNA 
quantification and finally (V) platinum determination. All of those experiments carry a 
liability of an individual error. Nevertheless, the results presented here indicate that 
PDIA1 may be a worthwhile target to be investigated in the context of acquired 
cisplatin resistance. 
5.4.2 Effects of pharmacologic inhibition of PDIA1 
Transient genetic modifications by siRNA treatment of various cellular proteins other 
than PDIA1, have been investigated in preclinical settings multiple times. The next 
step would be the in vivo treatment with siRNA, which is already under investigation 
in animals as well as in humans (see section 5.2). However, the most common 
therapeutic option used clinically to inhibit the function of a target is still the 
pharmacological inhibition. Thus, the potential of the recently developed PDIA1 
inhibitor PACMA31 to reverse cisplatin resistance was investigated. PACMA31 
covalently binds to Cys397/Cys400 at the CG C motif of PDIA1’s active site, 
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abolishing its intracellular function [140]. At the same time, this binding may block a 
predominant binding site of cisplatin [147]. 
PACMA31 shows comparable cytotoxicity in A2780/A2780cis cells as in the OVCAR-
3 cell line for which an EC50 of 0.32 µM was reported [140]. Interestingly, A2780cis 
cells did not show any resistance to PACMA31 with a resistance factor of only 1.2. 
The results suggest that PACMA31 overcomes cisplatin resistance in A2780cis cells 
by its ability to inhibit PDIA1. The stronger effect of a pharmacological inhibition may 
be a result of the irreversible inhibition of PDIA1 by PACMA31, which blocks the 
function of the protein to a greater extent than a siRNA knockdown. As the 
sensitizing effect by PACMA31 was much stronger than that of a PDIA1 knockdown, 
one may speculate that a knockdown to just below 50% of the basal level may be 
insufficient to remarkably limit the protein function. Results from DNA platination 
studies suggest that the synergistic effect of cisplatin and PACMA31 is not mediated 
by an increased amount of platinum bound to DNA. The effect is potentially induced 
by the impaired ability of the cell to manage the ER stress imposed by cisplatin. 
Inactive PDIA1 may be further amplifying the effect of PACMA31. The intact protein 
may prevent the cell from initiating compensational up-regulation of other chaperone 
molecules such as other protein disulfide isomerases. This may also explain the 
difference between the smaller effects found after the siRNA knockdown compared 
to the pharmacological inhibition. Altogether, the results suggest that beside 
irreversible PDIA1 inhibition there may be additional or alternative underlying 
mechanisms, e.g. an elevation of the ER stress level. The assumption of an 
alternative mechanism is also supported by the fact that PACMA31 is per se highly 
cytotoxic on these cells. 
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Nevertheless, this is the first study that manifests a synergistic interaction of 
PACMA31 and cisplatin in their ability to inhibit the growth of cancer cells. As 
postulated by Chou, it is of paramount importance for drug combinations in cancer 
therapy to exhibit synergy especially at high EC concentrations (higher than EC90) 
[192], in the best case eradicating all cancer cells. Our results show a synergistic 
effect of PACMA31 and cisplatin for concentrations above the respective EC75 in 
resistant cells. This indicates that a combined treatment of cisplatin and PACMA31 
may improve the therapy outcome in resistant ovarian cancer. 
In the meantime various other small molecule, irreversible PDIA1 inhibitors have 
been reported such as 16F16, juniferdin and analogues of P1 [193–195]. First 
described in 2014, members of the T8 class appear to be interesting candidate 
molecules for further development [196]. T8 and its derivatives are the first reversible 
PDIA1 inhibitors and show a high specificity for PDIA1. They have been shown to 
sensitize tumor cells to chemotherapeutic agents, such as etoposide or doxorubicin 
[196]. Kaplan et al. recently reported another reversible PDIA1 inhibitor, LOC14, 
which shows nanomolar potency [197]. This inihibitor binds adjacent to the active site 
cysteines of PDIA1, thus oxidizing PDIA1. Because of the high similarity of the 
binding site between PDIA1 and PDIA3 the authors suggest that LOC14 may 
simultaneously react with PDIA3 [197]. For 16F16, it has also been shown, that it 
binds both isoforms PDIA1 and PDIA3 investigated here [193]. This may also hold 
true for PACMA31. Further studies to identify the PACMA31 binding site in PDIA3 
and cisplatin binding sites in PDIA1 and PDIA3 are required. It seems reasonable to 
further improve the existing inhibitors by molecular modeling approaches and lead 
optimization of these structures to further increase their specificity. The evaluation of 
these compounds as co-therapy with cisplatin and other platinum analogues in 
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ovarian cancer but also other entities is warranted based on these first promising 
results. 
5.5 Contribution of PDIA3 to acquired cisplatin resistance 
As mentioned in section 1.4.2, PDIA3 is the closest homologue of PDIA1 among the 
identified protein disulfide isomerases, showing about 50% sequence identity in the 
catalytical active domains a and a’ [198]. Structural differences between the b and b’ 
domains of the proteins may explain the functional differences between the two 
chaperones. The differing surface charges of the b and b’ domains of PDIA3 support 
the binding of calnexin and calreticulin [198]. This important step in the folding of 
glycoproteins was only described for PDIA3 and not PDIA1 [199]. Additionally, the 
binding of calnexin increases the enzymatic activity of PDIA3 remarkably [200]. 
The knockdown of PDIA3 showed no effect on cisplatin cytotoxicity, implying that the 
PDIA3 knockdown is not able to sensitize A2780 or A2780cis cells to cisplatin 
treatment in accordance with the apoptosis results. Here, no additional apoptosis 
induction was detectable after knockdown and cisplatin treatment. The effects of 
cisplatin may have been covered by the huge impact of the PDIA3 knockdown itself, 
which increased the number of apoptotic cells. After compensating for the 
knockdown influence by calculating the ratio of apoptotic cells after knockdown and 
cisplatin treatment to knockdown alone, no effect was observed. A toxic effect of 
complete catalytic inhibition or shRNA inhibition of PDIA1 and PDIA3 has been 
shown by Hoffstrom et al. in PC12 cells [193]. One explanation may be the slightly 
more efficient siRNA knockdown of PDIA3 (A2780: ~40% or A2780cis: ~20%) over 
PDIA1 (A2780: ~45% or A2780cis: ~50%). This may have led to the extended 
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detrimental cellular responses (increased apoptosis initiation) after PDIA3 
knockdown. 
DNA platination was significantly increased after 4 h incubation with 100 µM cisplatin 
in A2780 cells. After 24 h incubation with 5 µM the effect was not detectable. The 
resistant cells showed no difference in DNA platination after PDIA3 knockdown under 
both experimental conditions. The results imply that the increased amount of 
platinum bound to DNA had no effect on the cells. As stated earlier the knockdown 
had a huge impact on cells which may have led to an increase in membrane 
permeability in A2780 cells. This would have simplified the uptake of cisplatin via 
passive diffusion leading to the increased DNA platination after 4 h treatment. The 
role of this effect diminishes over time, leading to different results for 24 h treatment. 
Coppari et al. described a nuclear localization of PDIA3 [201]. Furthermore, it was 
shown that cisplatin induces the binding of PDIA3 to DNA in the nucleus. As it was 
shown in our project by Sandra Kotz that CFDA-cisplatin interacts with PDIA3, which 
may be responsible for an increased platinum amount detected at the DNA level. 
This effect has been described for mitomycin C, which may be shuttled to DNA by 
PDIA3 [202]. 
Zhao et al. described the reduction of apoptotic signaling after pharmacological 
inhibition of PDIA1 and PDIA3 with securinine, thiomuscimol, or bacitracin [203]. 
These results contradict the results presented here. However, it has to be noted that 
bacitracin is by far not as specific in inhibiting PDIA1 and PDIA3 as PACMA31 is 
[204]. One study showed that bacitracin analogues vary in their IC50 for PDI inhibition 
from 20 µM (bacitracin F) to 1050 µM (bacitracin B) questioning the results of Zhao et 
al. [203,205]. In human endothelial cells the siRNA knockdown of PDIA3 appeared to 
regulate the tunicamycin-induced apoptosis, protecting the cell from apoptosis and 
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increasing the unfolded protein response by up-regulation of GRP78 expression 
[206]. This contradicts the hypothesis that a PDIA3 knockdown itself may be harmful 
for the cells per se, but as suggested earlier, these results may be cell line-
dependent. To investigate the contribution of PDIA1 and PDIA3 further, it may be 
helpful to perform a simultaneous knockdown of both proteins. However, this 
approach needs special precautions as the effects of a simultaneous knockdown on 
cell viability have to be closely monitored.  
In contrast to the results presented before, Tufo et al. found no contribution of PDIA1 
and PDIA3 to cisplatin resistance in NSCLC, but found some relevance for PDIA4 
and PDIA6. Cell death was induced by genetic and pharmacological inhibition of 
PDIA4 and PDIA6. PDIA4 inhibition acted by restoring the apoptosis pathway, while 
PDIA6 acted by a non-canonical cell death pathway [207]. Interestingly, PDIA6 has 
been found to interact with CFDA-cisplatin as well and may be an interesting target 
for future studies [111]. When comparing the results by Tufo et al. with the results for 
PDIA1 and PDIA3 presented here, proteins of the PDI family seem to act cell type-
specific [207]. 
5.6 Clinical relevance of intracellular binding partners for cisplatin 
resistance 
Beside the nuclear DNA, intracellular partners interacting with cisplatin have been 
associated with the impairment of efficacy, emergence of resistance and toxicity of 
cisplatin [67]. Among these non-DNA targets inside the cell are peptides, proteins, 
RNA, and phospholipids. At the same time other intracellular molecules interacting 
with cisplatin have been suggested to support cisplatin cytotoxicity, for example the 
mitochondrial DNA [208]. Further complexity to this ambivalent problem of the 
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cisplatin effect inside a cell is added by the cell type-specific action of some proteins, 
which may exert their functions in various ways in different tissue types. Therefore, 
the identified molecules that interact with cisplatin need to be thoroughly evaluated to 
determine their contribution to cisplatin action and to assess the clinical relevance for 
patients. 
Several lines of evidence point to a multifactorial ‘symphony’ of mechanisms which 
underlie cisplatin resistance in ovarian cancer patients. One of the mechanisms 
appears to be the intracellular detoxification of cisplatin by interacting with molecules. 
Various interacting partners mediate resistance of tumor cells to cisplatin in patients. 
Some interacting partners identified and their respective relevance are reviewed 
here. 
Diadenosine tetraphosphate (Ap4A), an intracellular dinucleotide, is among the 
intracellular interacting partners of cisplatin, which has been shown to form a 1:1 
complex with cisplatin in vitro [209]. As Ap4A is involved in the induction of apoptosis 
or DNA repair, interaction of cisplatin with Ap4A may facilitate or reduce cell death 
[210]. Recent research showed that Ap4A levels significantly increased after 
treatment of different cell lines with non-cytotoxic concentrations of the DNA cross-
linking agent mitomycin C. Further experimental evidence suggests that Ap4A aids 
the cellular survival after DNA damage [211]. In a cell culture model, Ap4A analogues 
showed an apoptosis-inducing effect on HEK293T cells by acting as a substrate for 
the proapoptotic fragile histidine triad (FHIT) protein. The proapoptotic activity of 
FHIT correlated with its substrate binding affinity. Analogues that showed a high 
affinity for the FHIT protein thus induced apoptosis and may therefore translate into 
clinical practice as an anticancer therapy [212]. 
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The role of glutathione (GSH) in cisplatin resistance is controversially discussed in 
the scientific literature. After chronic exposure of cultured cells to increasing cisplatin 
concentrations to generate resistant sublines, a high intracellular glutathione 
concentration correlated with a resistant cellular phenotype [213,214]. The correlative 
nature of the studies limits the generalization of the results. Furthermore, in human 
tumor xenografts it was impossible to reproduce these observations [215]. Depleting 
cells of GSH by treatment with buthionine sulfoximine (BSO) resulted in increased 
sensitivity to platinum drugs [216,217]. On the contrary, others found no correlation 
between GSH depletion and cisplatin sensitivity in cultured cells [218]. As these 
results show, it is currently unclear if elevated GSH levels are responsible for 
resistance or if they are a mere cellular reaction induced by cisplatin. In the clinical 
setting, a GSH substitution rather than depletion by administration of GSH was 
investigated, in order to ameliorate cisplatin-induced neurotoxicity, possibly by the 
ability of GSH to limit the accumulation of cisplatin in the dorsal root ganglia. Results 
of a systematic review suggested a small neuroprotective effect of GSH, but the 
studies showed several limitations, such as small sample size and variability in 
outcome measurements [219]. 
Metallothioneins (MT) are avid intracellular interacting partners of cisplatin, with their 
reaction with cisplatin progressing about 20 times faster than with GSH [98]. Cisplatin 
resistance has been associated with an increased expression of MT both in vitro as 
well as in vivo [220,221]. The clinical perspective of an interference with or a 
depletion of MTs in cancer patients to increase cisplatin efficacy is poor as adverse 
effects of this approach have already been reported, such as hepatotoxicity and 
nephrotoxicity [222,223]. 
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Heat shock protein 90 (HSP90) is the most abundant molecular chaperone in the 
cytosol, exerting several essential functions such as protein aggregation prevention 
and degradation [224]. Overexpression of HSP90 has been described for myeloma 
cancers [225]. Furthermore, cisplatin has been shown to bind HSP90 at the carboxyl 
terminal and the amino terminal domain. This interaction inhibits the aggregation 
prevention activity of HSP90 towards client proteins [226]. Clinical importance for 
HSP90 may be introduced by small-molecule inhibitors of HSP90 function, such as 
geldanamycin or raidicicol [227]. Derivatives of geldanamycin (e.g. 17-allylamino-17-
demethoxygeldanamycin (17-AAG)) in combination therapies with paclitaxel are 
currently in clinical development. Second generation synthetic HSP90 inhibitors are 
also under investigation and clinical evaluation in combination therapies for different 
cancer entities [227].  
The clinical relevance of the intracellular interacting partners of CFDA-cisplatin found 
in this study needs to be further evaluated. PDIA1 appears to be the most promising 
candidate. As stated earlier, several small molecule inhibitors have been recently 
published (5.4.2). Their efficacy in the treatment of cancer needs to be evaluated in 
cell models. If they prove to be effective, animal studies need to evaluate the safety 
of these inhibitors. As the ER stress response and the folding of nascent proteins is 
conducted, at least in part, by PDIA1, dose-dependent side effects of the inhibitors 
are conceivable. If safety can be confirmed in animals, it is essential to evaluate the 
efficacy and safety in clinical studies before the drugs can enter therapy regimens for 
cancer. Another therapeutic approach that could make use of PDIA1 is the 
knockdown of this protein in ovarian cancer patients. Some studies already 
presented promising results for cancer treatment by the siRNA-mediated down-
regulation of proteins in animal models [228]. Others reported the improvement of the 
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therapeutic efficacy of chemotherapies by co-delivery of siRNA directed against 
specific proteins [170]. The next step in the development of siRNA therapeutics 
includes the evaluation of these treatments in humans [165]. Another important 
research focus is the control of drug resistance using siRNA approaches [168]. 
Knockdown of validated target proteins, shown to play an important role in drug 
resistance, has the potential to augment the efficacy of anti-cancer drugs.  
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6 CONCLUSION AND OUTLOOK 
This project presents an approach to identify and assess the relevance of 
intracellular proteins interacting with CFDA-cisplatin. Besides, this study describes 
the methodology and results of a screening approach applied to previously identified 
proteins interacting with CFDA-cisplatin, in order to evaluate their contribution to 
acquired cisplatin resistance in an ovarian carcinoma cell line pair. In conclusion, the 
results suggest a contribution of PDIA1 to acquired cisplatin resistance in A2780cis 
cells. A pharmacologic inhibition of PDIA1 by PACMA31 synergistically increases 
cisplatin cytotoxicity. The results imply no direct contribution of the proteins GRP78 
and PDIA3 to acquired cisplatin resistance. 
In the simultaneously performed screening study, several other proteins interacting 
with CFDA-cisplatin have been identified. Some of those appear to be interesting 
targets for further evaluation, as they have already been associated with resistance 
to anticancer therapy in the scientific literature, some of them even in the context of 
acquired cisplatin resistance. 
The complexity of intracellular signaling pathways may be limiting the efficacy of a 
single protein knockdown by compensation mechanisms. Thus, an approach to 
knockdown several proteins at the same time may provide new possibilities to 
improve the efficacy of a cytotoxic agent. Results have to be interpreted with caution 
as the multiple protein knockdown may affect cellular functions in an unexpected 
extent. For example, protein disulfide isomerases are essential for normal cell growth 
as they fold newly synthesized proteins. After interference with several of these 
crucial proteins, it is likely that a critical disturbance of their cellular function in healthy 
cells would lead to severe side effects. 
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Pharmacological inhibition, which is still the most common way for chemotherapeutic 
interventions, needs to be further improved. There are now several small molecule 
inhibitors for PDIA1 reported (PACMA31, 16F16, P1, and T8), which show efficacy in 
cancer cell models or even animal models. By rational drug design, these 
compounds may become suitable for use in humans, further increasing the efficacy 
and at the same time limiting the side effects. This study suggests that the 
therapeutic efficacy of cisplatin in ovarian cancer may be synergistically improved in 
combination therapy with PDIA1 inhibitors. This needs to be investigated in cell 
models of other cancer entities and, if the efficacy is confirmed, in animal models. 
Other established chemotherapeutic regimens may also be combined with PDIA1 
inhibitors leading to therapeutic benefits for patients. 
During this study several new questions arose: 
 Why is an effect of PDIA1 interference on cisplatin cytotoxicity not associated 
with an increased DNA platination? 
 Why does a PDIA3 knockdown lead to a markedly increased apoptosis 
induction level in contrast to a PDIA1 knockdown? 
 Why does cisplatin treatment not add to apoptosis induction after PDIA3 
knockdown but after PDIA1 knockdown? 
These questions need to be addressed in future studies to deepen our understanding 
of the multifactorial nature of acquired cisplatin resistance and to improve our 
capability to control resistance in the clinical setting.  
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7 SUMMARY 
Intracellular binding of cisplatin to non-DNA partners, such as proteins, has received 
increasing attention as an additional mode of action as well as a mechanism of 
resistance. In this project three cisplatin-interacting proteins, two members of the 
protein disulfide isomerase family (PDIA1 and PDIA3) and 78 kDA glucose-regulated 
protein (GRP78), have been identified by means of the fluorescent cisplatin analogue 
CFDA-cisplatin. These proteins have been investigated regarding their contribution to 
acquired cisplatin resistance using a sensitive and cisplatin-resistant ovarian cancer 
cell line pair (A2780/A2780cis). 
Cisplatin cytotoxicity after knockdown of PDIA1, PDIA3, or GRP78 was assessed 
using the MTT assay. Whereas PDIA1 knockdown led to increased cisplatin 
cytotoxicity in resistant A2780cis cells, PDIA3 and GRP78 knockdown showed no 
influence. The cisplatin-induced apoptosis after knockdown of the respective proteins 
was evaluated by flow cytometry with Annexin V and propidium iodide staining. 
Compared to control cells, PDIA1 knockdown led to an increase of apoptotic 
A2780cis cells after cisplatin treatment. The knockdown of GRP78 showed no effect. 
The knockdown of PDIA3 readily displayed a strong apoptosis-inducing effect, even 
without cisplatin treatment. DNA platination, assessed by ICP-MS analysis, was not 
altered after PDIA1 knockdown suggesting an alternative mechanism accounting for 
the increased cisplatin cytotoxicity. Co-incubation with the PDIA1 inhibitor PACMA31 
re-sensitized A2780cis cells to cisplatin treatment. PACMA31 co-incubation with 
cisplatin did not alter the DNA platination in A2780 and A2780cis cells. Combination 
index analysis revealed that the combination of cisplatin and PACMA31 acts 
synergistically. 
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The results warrant further evaluation of PDIA1 as promising target for 
chemotherapy. The pharmacological inhibition of PDIA1 by PACMA31 in combination 
with cisplatin may serve as a new therapeutic approach in ovarian cancer treatment. 
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Appendix A  
HPLC method development 
Chromatograms  
Aqueous phase adjusted to pH 4.5 
 
Aqueous phase adjusted to pH 5.5 
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Aqueous phase adjusted to pH 6.5 
 
Aqueous phase adjusted to pH 7.5 
 
Aqueous phase adjusted to pH 8.0 
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Appendix B  
Influence of GRP78 knockdown 
B1 SiRNA knockdown 
GRP78 expression in A2780 and A2780cis cells with negative knockdown and PDIA1 
knockdown in relation to cells without knockdown (results of individual testing) 
 A2780 cells A2780cis cells 
 
negative 
knockdown 
GRP78 
knockdown 
negative 
knockdown 
GRP78 
knockdown 
 1.112 0.607 0.625 0.265 
 0.767 0.214 0.487 0.152 
 0.721 0.655 0.710 0.637 
 1.033 0.494 0.958 0.486 
  0.843  0.223 
  0.706  0.448 
Mean 0.908 0.587 0.695 0.369 
SD 0.193 0.216 0.198 0.185 
SEM 0.097 0.088 0.099 0.075 
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B2 Cytotoxicity of cisplatin 
Individual pEC50 values for cisplatin cytotoxicity in A2780 and A2780cis cells without 
knockdown, with negative knockdown and with GRP78 knockdown (results of 
individual testing) 
 A2780 cells A2780cis cells 
 
negative 
knockdown 
GRP78 
knockdown 
negative 
knockdown 
GRP78 
knockdown 
 5.301 5.121 4.769 4.601 
 5.265 5.191 4.656 4.830 
 5.529 5.409 4.868 4.704 
 5.513 5.540 4.869 4.788 
 5.299 5.424 4.914 4.715 
 5.436 5.191 4.890 4.779 
 5.301 5.364 4.717 4.661 
   4.761 4.513 
   4.561 4.601 
Mean 5.378 5.320 4.778 4.699 
SD 0.112 0.154 0.111 0.105 
SEM 0.042 0.058 0.039 0.037 
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B3 Apoptosis induction 
Percentage of late apoptotic, early apoptotic and viable A2780 cells without 
knockdown, with negative knockdown and with GRP78 knockdown without cisplatin 
treatment or with 10 µM cisplatin for 24 h (results of individual testing) 
 A2780 cells 
 Without cisplatin With 10 µM cisplatin for 24 h 
 
without 
knock-
down 
negative 
knock-
down 
GRP78 
knock-
down 
without 
knock-
down 
negative 
knock-
down 
GRP78 
knock-
down 
Late 
apoptotic 
cells 
3.79 3.22 4.54 19.1 5.11 5.27 
1.96 4.94 11 7.03 11.2 12.1 
6.87 9.36 10.3 28.4 16.9 17.6 
Mean 4.21 5.84 8.61 18.2 11.1 11.7 
SD 2.48 3.17 3.55 10.7 5.90 6.18 
SEM 1.43 1.83 2.05 6.19 3.40 3.57 
Early 
apoptotic 
cells 
3.43 5.57 7.36 11.7 10.1 10.1 
3.12 10.3 21.1 4.43 18.6 20.5 
3.90 1.25 6.2 11.2 7.81 11.7 
Mean 3.48 5.71 11.6 9.11 12.2 14.1 
SD 0.39 4.50 8.29 4.06 5.69 5.60 
SEM 0.23 2.61 4.79 2.34 3.28 3.23 
Viable 
cells 
92.8 91.2 88.1 69.2 84.9 84.6 
94.2 84.8 67.9 88.5 70.2 67.4 
89.2 89.4 83.5 60.4 75.3 70.7 
Mean 92.3 88.5 79.8 72.7 76.8 74.2 
SD 2.87 3.33 10.6 14.4 7.41 9.15 
SEM 1.66 1.92 6.11 8.31 4.28 5.28 
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Percentage of late apoptotic, early apoptotic and viable A2780cis cells without 
knockdown, with negative knockdown and with GRP78 knockdown without cisplatin 
treatment or with 10 µM cisplatin for 24 h (results of individual testing) 
 A2780cis cells 
 Without cisplatin With 10 µM cisplatin for 24 h 
 
without 
knock-
down 
negative 
knock-
down 
GRP78 
knock-
down 
without 
knock-
down 
negative 
knock-
down 
GRP78 
knock-
down 
Late 
apoptotic 
cells 
3.87 3.45 3.83 7.09 4.17 4.54 
3.83 6.49 5.45 10.40 6.67 3.98 
4.74 7.35 9.71 9.65 9.86 11.90 
Mean 4.15 5.76 6.33 9.05 6.90 6.81 
SD 0.51 2.05 3.04 1.74 2.85 4.42 
SEM 0.29 1.18 1.75 1.00 1.65 2.55 
Early 
apoptotic 
cells 
0.99 2.10 2.28 1.62 1.73 3.32 
1.03 7.16 8.16 2.14 9.47 3.59 
0.89 1.73 2.48 1.92 3.89 3.27 
Mean 0.97 3.66 4.31 1.89 5.03 3.39 
SD 0.07 3.03 3.34 0.26 3.99 0.17 
SEM 0.04 1.75 1.93 0.15 2.31 0.09 
Viable 
cells 
95.14 94.45 93.89 91.29 94.10 92.14 
95.14 86.35 86.39 87.46 83.86 92.43 
94.37 90.92 87.81 88.43 86.25 84.83 
Mean 94.88 90.57 89.36 89.06 88.07 89.80 
SD 0.45 4.06 3.98 1.99 5.36 4.31 
SEM 0.26 2.35 2.30 1.15 3.09 2.49 
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Appendix C  
Influence of PDIA1 knockdown 
C1 SiRNA knockdown 
PDIA1 expression in A2780 and A2780cis cells with negative knockdown and PDIA1 
knockdown in relation to cells without knockdown (results of individual testing) 
 A2780 cells A2780cis cells 
 
negative 
knockdown 
PDIA1 
knockdown 
negative 
knockdown 
PDIA1 
knockdown 
 1.50 0.33 1.00 0.50 
 1.07 0.53 1.31 0.41 
 0.56 0.47 1.34 0.47 
 0.73 0.30 0.52 0.44 
 0.61 0.63 1.00 0.53 
 0.69 0.48 1.25 0.70 
 1.25 0.51 1.01 0.29 
 1.50 0.25 0.63 0.54 
  0.40 1.06 0.62 
  0.51 0.59 0.22 
  0.53 1.00 0.50 
   1.29  
   1.09  
Mean 0.989 0.449 1.01 0.474 
SD 0.393 0.115 0.274 0.135 
SEM 0.139 0.035 0.076 0.041 
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C2 Cytotoxicity of cisplatin 
Individual pEC50 values for cisplatin cytotoxicity in A2780 and A2780cis cells without 
knockdown, with negative knockdown and with PDIA1 knockdown (results of 
individual testing) 
 A2780 cells A2780cis cells 
 
without 
knockdow
n 
negative 
knockdow
n 
PDIA1 
knockdow
n 
without 
knockdow
n 
negative 
knockdow
n 
PDIA1 
knockdow
n 
 5.458 5.323 5.631 5.017 4.939 5.032 
 5.377 5.216 5.394 4.876 4.849 4.973 
 5.435 5.406 5.644 4.917 4.818 5.009 
 5.266 5.450  4.802 4.747  
 5.234 5.409  4.843 4.889  
 5.439   4.864   
 5.357   4.844   
Mea
n 5.367 5.361 5.556 4.880 4.848 5.005 
SD 0.0877 0.0932 0.1407 0.0697 0.0726 0.0297 
SEM 0.0332 0.0417 0.0813 0.0264 0.0325 0.0172 
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C3 Apoptosis induction 
Percentage of late apoptotic. early apoptotic and viable A2780 cells without 
knockdown, with negative knockdown and with PDIA1 knockdown without cisplatin 
treatment or with 10 µM cisplatin for 24 h (results of individual testing) 
 A2780 cells 
 Without cisplatin With 10 µM cisplatin for 24 h 
 
without 
knock-
down 
negative 
knock-
down 
PDIA1 
knock-
down 
without 
knock-
down 
negative 
knock-
down 
PDIA1 
knock-
down 
Late 
apoptotic 
cells 
13.3 23.2 15.0 61.1 56.0 48.5 
5.05 13.3 14.7 60.1 39.2 37.5 
3.65 15.4 17.3 34.3 34.4 39.3 
Mean 7.33 17.3 15.7 51.8 43.2 41.8 
SD 5.21 5.22 1.42 15.2 11.3 5.90 
SEM 3.01 3.01 0.82 8.77 6.55 3.41 
Early 
apoptotic 
cells 
2.28 6.5 4.68 6.58 22.1 15.8 
2.12 1.17 0.98 5.71 2.20 2.17 
2.29 6.4 6.65 0.48 12.9 11.7 
Mean 2.23 4.69 4.10 4.26 12.4 9.89 
SD 0.10 3.05 2.88 3.30 9.96 6.99 
SEM 0.06 1.76 1.66 1.90 5.75 4.04 
Viable 
cells 
84.1 69.1 79.6 28.1 19.8 33.9 
92.7 81.6 80.7 31.6 52.4 56.1 
93.6 76.9 75.0 49.4 52.0 47.9 
Mean 90.1 75.9 78.4 36.4 41.4 46.0 
SD 5.24 6.31 3.02 11.4 18.7 11.2 
SEM 3.03 3.65 1.75 6.59 10.8 6.48 
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Percentage of late apoptotic. early apoptotic and viable A2780cis cells without 
knockdown. with negative knockdown and with PDIA1 knockdown without cisplatin 
treatment or with 10 µM cisplatin for 24 h (results of individual testing) 
 A2780cis cells 
 Without cisplatin With 10 µM cisplatin for 24 h 
 
without 
knock-
down 
negative 
knock-
down 
PDIA1 
knock-
down 
without 
knock-
down 
negative 
knock-
down 
PDIA1 
knock-
down 
Late 
apoptotic 
cells 
4.64 8.09 7.09 13.5 11.0 22.5 
9.00 11.3 7.25 21.2 12.0 16.3 
13.5 23.7 22.1 20.9 16.7 25.6 
Mean 9.05 14.4 12.2 18.5 13.2 21.5 
SD 4.43 8.24 8.62 4.36 3.04 4.74 
SEM 2.56 4.76 4.98 2.52 1.76 2.73 
Early 
apoptotic 
cells 
0.37 0.92 0.55 0.78 1.02 3.02 
2.36 2.15 1.08 2.77 2.00 4.18 
0.95 3.39 3.29 0.40 2.77 4.46 
Mean 1.23 2.15 1.64 1.32 1.93 3.89 
SD 1.02 1.24 1.45 1.27 0.88 0.76 
SEM 0.59 0.71 0.84 0.73 0.51 0.44 
Viable 
cells 
94.9 90.5 92.2 85.5 87.6 75.1 
88.6 86.0 90.9 76.0 85.4 78.9 
80.7 71.7 73.7 73.3 80.0 69.4 
Mean 88.1 82.7 85.6 78.3 84.3 74.5 
SD 7.12 9.82 10.3 6.41 3.91 4.78 
SEM 4.11 5.67 5.96 3.70 2.26 2.76 
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C4 DNA platination 
DNA platination [pg platinum/ng DNA] after incubation with 100 µM cisplatin for 4 h in 
A2780 and A2780cis cells without knockdown, with negative knockdown and with 
PDIA1 knockdown (results of individual testing) 
 A2780 cells A2780cis cells 
 
without 
knock-
down 
negative 
knock-
down 
PDIA1 
knock-
down 
without 
knock-
down 
negative 
knock-
down 
PDIA1 
knock-
down 
 201.4 249.3 169.8 49.1 129.8 103.8 
 224.4 200.8 203.2 62.2 96.1 106.1 
 239.7 190.1 215.2 67.1 94.6 172.4 
 215.9 183.5 205.5  133.0  
Mean 220.3 205.9 198.4 59.4 113.4 127.4 
SD 16.0 29.8 19.8 9.3 20.8 38.9 
SEM 8.0 14.9 9.9 5.4 10.4 22.5 
 
DNA platination [pg platinum/ng DNA] after incubation with 5 µM cisplatin for 24 h in 
A2780 and A2780cis cells without knockdown, with negative knockdown and with 
PDIA1 knockdown (results of individual testing) 
 A2780 cells A2780cis cells 
 
without 
knock-
down 
negative 
knock-
down 
PDIA1 
knock-
down 
without 
knock-
down 
negative 
knock-
down 
PDIA1 
knock-
down 
 13.7 23.8 20.4 6.4 24.3 15.6 
 13.9 19.1 25.3 11.6 21.3 12.1 
 22.8 17.7 21.5 20.4 17.5 21.9 
 19.4  20.6  28.0  
Mean 17.5 20.2 21.9 12.8 22.8 16.5 
SD 4.4 3.2 2.3 7.1 4.5 5.0 
SEM 2.2 1.9 1.1 4.1 2.2 2.9 
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Appendix D Influence of co-treatment with PACMA31 
D1 Cytotoxicity of PACMA31 
Individual pEC50 and pEC10 values for PACMA31 cytotoxicity in A2780 and A2780cis 
cells (results of individual testing) 
 
 
  
 A2780 cells A2780cis cells 
 pEC50 pEC10 pEC50 pEC10 
 6.320 6.452 6.085 6.620 
 6.315 6.451 6.446 6.142 
 6.400 6.580 6.369 6.450 
 6.436 6.637 6.468 6.495 
 6.502 6.596 6.491 6.544 
 6.614 6.955 6.721 6.588 
 6.748 7.001 6.570 6.864 
 6.755 7.023 6.700 6.597 
 6.700 6.986 6.587 6.915 
 6.773 7.080 6.416 6.640 
 6.292 6.474 6.075 6.465 
 6.347 6.559 6.081 6.186 
 6.383 6.635 6.061 6.137 
 6.329 6.564 6.497 6.184 
 6.188 6.312  6.582 
  6.159  6.599 
  6.175  6.475 
  6.437  6.631 
    6.378 
Mean 6.47 6.62 6.40 6.50 
SD 0.195 0.286 0.233 0.220 
SEM 0.050 0.067 0.062 0.050 
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D2 Cytotoxicity of a combination of cisplatin and PACMA31 
Individual pEC50 values for cisplatin cytotoxicity in A2780 and A2780cis cells without 
and with co-treatment with 0.2 µM PACMA31 (results of individual testing) 
 A2780 cells A2780cis cells 
 Cisplatin 
Cisplatin + 
PACMA31 
Cisplatin 
Cisplatin + 
PACMA31 
 5.692 5.663 5.059 5.161 
 5.809 5.678 5.160 5.157 
 5.708 5.898 5.084 5.507 
  5.777  5.599 
  5.914  5.491 
  5.917  5.521 
Mean 5.737 5.798 5.102 5.406 
SD 0.064 0.112 0.055 0.195 
SEM 0.037 0.046 0.032 0.080 
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D3 Combination index (CI) of cisplatin and PACMA31 
CI values determined EC50. EC75. EC90 and EC95 of the combination of cisplatin and 
PACMA31 in A2780 cells 
 A2780 cells 
 EC50 EC75 EC90 EC95 
 1.61 1.13 0.794 0.624 
 1.50 1.06 0.740 0.582 
 1.81 1.19 0.784 0.591 
 1.67 1.12 0.756 0.578 
 1.59 1.07 0.723 0.553 
 1.43 1.09 0.871 0.777 
 1.67 1.21 0.927 0.801 
 0.86 0.817 0.786 0.770 
 0.98 0.937 0.907 0.892 
Mean 1.46 1.07 0.81 0.69 
SD 0.325 0.124 0.074 0.124 
SEM 0.108 0.041 0.025 0.041 
 
  
APPENDIX 135 
 
CI values determined for EC50. EC75. EC90 and EC95 of the combination of cisplatin 
and PACMA31 in A2780cis cells 
 A2780cis cells 
 EC50 EC75 EC90 EC95 
 1.298 0.818 0.516 0.377 
 1.175 0.737 0.463 0.337 
 0.657 0.457 0.321 0.254 
 1.389 0.986 0.708 0.568 
 1.273 0.901 0.645 0.517 
 0.620 0.624 0.632 0.639 
 0.699 0.686 0.677 0.674 
 0.822 0.803 0.785 0.773 
 0.936 0.912 0.888 0.872 
Mean 0.985 0.769 0.626 0.557 
SD 0.302 0.164 0.172 0.206 
SEM 0.101 0.055 0.057 0.069 
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Appendix E  
Influence of PDIA3 knockdown 
E1 SiRNA knockdown 
PDIA3 expression in A2780 and A2780cis cells with negative knockdown and PDIA3 
knockdown in relation to cells without knockdown (results of individual testing) 
 A2780 cells A2780cis cells 
 
negative 
knockdown 
PDIA3 
knockdown 
negative 
knockdown 
PDIA3 
knockdown 
 0.470 1.006 0.870 0.350 
 0.533 1.137 0.652 0.130 
 0.209  1.224 0.014 
Mean 1.072 0.404 0.915 0.165 
SD 0.093 0.172 0.288 0.171 
SEM 0.066 0.099 0.167 0.098 
  
APPENDIX 137 
 
E2 Cytotoxicity of cisplatin 
Individual pEC50 values for cisplatin cytotoxicity for A2780 and A2780cis cells without 
knockdown, with negative knockdown and with PDIA3 knockdown (results of 
individual testing) 
 A2780 cells A2780cis cells 
 
without 
knock-
down 
negative 
knock-
down 
PDIA3 
knock-
down 
without 
knock-
down 
negative 
knock-
down 
PDIA3 
knock-
down 
 5.458 5.323 5.356 5.017 4.939 4.687 
 5.377 5.216 5.514 4.876 4.849 4.796 
 5.435 5.406 5.378 4.917 4.818 4.851 
 5.266 5.450 5.288 4.802 4.747 4.782 
 5.234 5.409 5.323 4.843 4.889 4.838 
 5.439  5.462 4.864  4.814 
 5.357   4.844   
Mean 5.367 5.361 5.387 4.880 4.848 4.795 
SD 0.088 0.093 0.086 0.070 0.073 0.059 
SEM 0.033 0.042 0.035 0.026 0.033 0.024 
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E3 Apoptosis induction 
Percentage of late apoptotic, early apoptotic and viable A2780 cells without 
knockdown, with negative knockdown and with PDIA1 knockdown without cisplatin 
treatment or with 10 µM cisplatin for 24 h (results of individual testing) 
 A2780 cells 
 Without cisplatin With 10 µM cisplatin for 24 h 
 
without 
knock-
down 
negative 
knock-
down 
PDIA1 
knock-
down 
without 
knock-
down 
negative 
knock-
down 
PDIA1 
knock-
down 
Late 
apoptotic 
cells 
7.11 7.23 45.4 18.7 36.6 58.5 
7.72 54.0 53.2 22.5 49.8 61.8 
2.80 23.4 25.1 14.8 37.1 36.3 
Mean 5.88 28.2 41.2 18.7 41.2 52.2 
SD 2.68 23.8 14.5 3.85 7.48 13.9 
SEM 1.55 13.7 8.38 2.22 4.32 8.01 
Early 
apoptotic 
cells 
2.29 1.09 5.72 6.56 6.38 6.52 
2.72 4.20 4.08 10.5 5.48 6.40 
1.97 3.89 5.41 7.99 7.42 8.64 
Mean 2.33 3.06 5.07 8.35 6.43 7.19 
SD 0.38 1.71 0.87 1.99 0.97 1.26 
SEM 0.22 0.99 0.50 1.15 0.56 0.73 
Viable 
cellls 
90.5 91.5 46.1 74.3 56.3 32.1 
89.2 69.4 39.9 66.4 43.3 29.3 
95.1  67.2 76.7 53.2 53.5 
Mean 91.6 80.5 51.1 72.5 50.9 38.3 
SD 3.10 15.6 14.3 5.39 6.79 13.2 
SEM 1.79 11.05 8.26 3.11 3.92 7.64 
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Percentage of late apoptotic, early apoptotic and viable A2780cis cells without 
knockdown, with negative knockdown and with PDIA3 knockdown without cisplatin 
treatment or with 10 µM cisplatin for 24 h (results of individual testing) 
 A2780cis cells 
 Without cisplatin With 10 µM cisplatin for 24 h 
 
without 
knock-
down 
negative 
knock-
down 
PDIA3 
knock-
down 
without 
knock-
down 
negative 
knock-
down 
PDIA3 
knock-
down 
Late 
apoptotic 
cells 
6.61 31.8 20.3 18.4 14.4 18.3 
15.1 17.2 31.8 28.1 30.5 39.7 
3.28 8.80 10.2 10.3 25.1 14.2 
Mean 8.33 19.3 20.8 18.9 23.3 24.1 
SD 6.09 11.6 10.8 8.91 8.19 13.7 
SEM 3.52 6.72 6.24 5.15 4.73 7.91 
Early 
apoptotic 
cells 
0.51 4.51 1.67 1.86 1.71 1.36 
2.30 0.98 2.49 5.56 2.72 3.40 
0.62 0.76 1.97 1.90 1.74 2.69 
Mean 1.14 2.08 2.04 3.11 2.06 2.48 
SD 1.00 2.10 0.42 2.13 0.58 1.04 
SEM 0.58 1.21 0.24 1.23 0.33 0.60 
Viable 
cells 
92.8 62.7 75.8 78.9 83.6 78.3 
82.2 81.7 65.3 64.6 66.4 56.3 
96.0 90.1 87.6 87.7 72.6 82.7 
Mean 90.3 78.2 76.2 77.1 74.2 72.4 
SD 7.22 14.0 11.2 11.7 8.71 14.1 
SEM 4.17 8.10 6.44 6.73 5.03 8.17 
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E4 DNA platination 
DNA platination [pg platinum/ng DNA] after incubation with 100 µM cisplatin for 4 h in 
A2780 and A2780cis cells without knockdown, with negative knockdown and with 
PDIA3 knockdown (results of individual testing) 
 A2780 cells A2780cis cells 
 
without 
knock-
down 
negative 
knock-
down 
PDIA3 
knock-
down 
without 
knock-
down 
negative 
knock-
down 
PDIA3 
knock-
down 
 327.8 349.7 365.7 82.02 98.47 115.3 
 362.2 319.9 363.5 125.4 188.7 237.3 
 379.0 328.4 429.4 131.6 68.35 83.01 
Mean 356.3 332.7 386.2 112.9 118.5 145.2 
SD 26.1 15.3 37.4 27.0 62.6 81.4 
SEM 15.1 8.9 21.6 15.6 36.2 46.9 
 
DNA platination [pg platinum/ng DNA] after incubation with 5 µM cisplatin for 24 h in 
A2780 and A2780cis cells without knockdown, with negative knockdown and with 
PDIA3 knockdown (results of individual testing) 
 A2780 cells A2780cis cells 
 
without 
knock-
down 
negative 
knock-
down 
PDIA3 
knock-
down 
without 
knock-
down 
negative 
knock-
down 
PDIA3 
knock-
down 
 10.34 29.40 47.55 19.38 17.54 26.33 
 19.09 100.2 85.59 11.58 12.73 16.29 
Mean 14.72 64.80 66.57 15.48 15.14 21.31 
SD 6.187 50.06 26.90 5.515 3.401 7.099 
SEM 4.375 35.40 19.02 3.900 2.405 5.020 
 
 
